CN1315809C - Quinoline derivatives and their use as 5-HT6 ligands - Google Patents

Abstract

The present invention relates to quinoline compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R<1> and R<2> independently represent hydrogen or C1-6 alkyl or R<1> is linked to R<2> to form a group (CH2)2, (CH2)3 or (CH2)4; R<3>, R<4> and R<5> independently represent hydrogen, halogen, cyano, -CF3, -CF3O, C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl or a group -CONR<6>R<7>; m represents an integer from 1 to 4, such that when m is an integer greater than 1, two R<2> groups may instead be linked to form a group CH2, (CH2)2 or (CH2)3; n represents an integer from 1 to 3; p represents 1 or 2; A represents a group -Ar<1> or -Ar<2>Ar<3>; Ar<1>, Ar<2> and Ar<3> independently represent and aryl group or a heteroaryl group, both of which may be optionally substituted by one or more substituents having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

Description

Quinoline and its are as 5-HT 6The purposes of part

The present invention relates to have the new quinoline compound of pharmacological activity, their preparation method, the composition that contains them and their purposes in treatment CNS and other disease thereof.

WO98/27081 discloses a series of 5-HT of it is said₆Receptor antagonist is also claimed the aryl sulphur amine compound that can be used for treating various CNS diseases.GB-2341549, WO99/47516 and WO99/65906 disclose a series of indole derivativeses, and claim that it has 5-HT₆Receptor affinity.JP02262627 (JapanSynthetic Rubber company) discloses a series of substituted chinoline derivatives as Wavelength changing element.WO00/42026 (Novo Nordisk) discloses a series of quinoline and quinoxaline compounds as the GLP-1 agonist.

Had now found that a class is to 5-HT₆Acceptor also has the novel compound of affinity.Therefore, first aspect the invention provides formula (I) compound or pharmaceutically acceptable salt thereof or its solvate:

Wherein:

R¹And R²Represent hydrogen or C independently_1-6Alkyl or R¹Be connected to R²Last formation group (CH₂)₂, (CH₂)₃Or (CH₂)₄

R³, R⁴And R⁵Represent independently hydrogen, halogen, cyano group ,-CF₃,-CF₃O, C_1-6Alkyl, C_1-6Alkoxyl group, C_1-6Alkyloyl or group CONR⁶R⁷

R⁶And R⁷Represent hydrogen or C independently_1-6It is optional by the 5-7 of O or S atomic separation unit's fragrance or nonaromatic heterocycles that alkyl or can condense together forms;

M represents the integer of 1-4, thus when m be during greater than 1 integer, two R²Base can be connected to form group CH₂, (CH₂)₂Or (CH₂)₃

N represents putting in order of 1-3;

P represents 1 or 2;

A represents group-Ar¹Or-Ar²Ar³

Ar¹, Ar²And Ar³Represent aryl or heteroaryl independently, described aryl and heteroaryl can choose wantonly by one or more (for example, 1,2 or 3) identical or different substituting group replaces, and described substituting group is selected from: halogen, hydroxyl, cyano group, nitro, trifluoromethyl, trifluoromethoxy, C_1-6Alkyl, trifluoro-methanesulfonyl oxy, pentafluoroethyl group, C_1-6Alkoxyl group, aryl C_1-6Alkoxyl group, C_1-6Alkylthio, C_1-6Alkoxy C_1-6Alkyl, C_3-7Cycloalkyl C_1-6Alkoxyl group, C_1-6Alkyloyl, C_1-6Alkoxy carbonyl, C_1-6Alkyl sulphonyl, C_1-6Alkyl sulfinyl, C_1-6Alkyl sulphonyl oxygen base, C_1-6Alkyl sulphonyl C_1-6Alkyl, aryl sulfonyl, aryl sulfonyl oxygen base, aryl sulfonyl C_1-6Alkyl, C_1-6Alkyl sulfonyl amino, C_1-6Alkyl amido, C_1-6The amino C of alkyl sulfonyl_1-6Alkyl, C_1-6Alkyl amido C_1-6Alkyl, Arenesulfonyl amino, aryl amido group, Arenesulfonyl amino C_1-6Alkyl, aryl amido group C_1-6Alkyl, aroyl, aroyl C_1-6Alkyl, aryl C_1-6Alkyloyl or group CONR⁸R⁹Or SO₂NR⁸R⁹, R wherein⁸And R⁹Represent hydrogen or C independently_1-6It is optional by the 5-7 of O or S atomic separation unit's fragrance or nonaromatic heterocycles that alkyl or can condense together forms.

Alkyl no matter be independent or as the part of other group, can be a straight or branched, and alkoxyl group and alkyloyl are explained equally.Alkyl is more preferably C_1-4Alkyl, for example, methyl or ethyl.Except as otherwise noted, the term " halogen " of the present invention's use refers to be selected from the group of fluorine, chlorine, bromine or iodine.

Term " aryl " comprises phenyl and naphthyl.

Term " heteroaryl " refers to contain 1-3 heteroatomic 5-7 unit's monocyclic aromatic rings or condensed 8-10 unit dicyclo aromatic ring that is selected from oxygen, nitrogen and sulphur.The suitable example of described monocyclic aromatic rings comprises thienyl, furyl, pyrryl, triazolyl, imidazolyl,  azoles base, thiazolyl,  di azoly, isothiazolyl, different  azoles base, thiadiazolyl group, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl.The suitable example of described fused aromatic rings comprises benzo-fused aromatic ring, for example, quinolyl, isoquinolyl, quinazolyl, quinoxalinyl, cinnolines base, naphthyridinyl, indyl, indazolyl, pyrrolopyridinyl, benzofuryl, benzothienyl, benzimidazolyl-, benzoxazol base, benzisoxa  azoles base, benzothiazolyl, benzisothiazole base, benzo  di azoly and diazosulfide base etc.As mentioned above, heteroaryl can link to each other with the molecule rest part by carbon atom, perhaps, links to each other with the molecule rest part by suitable nitrogen-atoms (if present), unless above indicate in addition.

What should know is, when the substituting group of above-mentioned aryl or heteroaryl surpassed one, described substituting group can connect into ring, and for example, carboxyl and amino can be connected to form amide group.

Preferably, R¹Expression hydrogen, methyl, ethyl, sec.-propyl, isobutyl-or 2, the 2-dimethyl propyl.More preferably, R¹Expression hydrogen or methyl, particularly hydrogen.

Preferably, R²Expression hydrogen, methyl (for example, 3-methyl, 2-methyl, 3,3-dimethyl or 2,5-dimethyl) or and R¹Be connected to form group (CH₂)₃More preferably, R²Expression hydrogen or methyl (for example, the 3-methyl), particularly hydrogen.

Preferably, R³Expression hydrogen, methyl (for example, 6-methyl) or halogen (for example, 7-chlorine).More preferably, R³Expression hydrogen.

Preferably, R⁴And R⁵Represent hydrogen or methyl, particularly hydrogen independently.

Preferably, n represents 1.

Preferably, m and p represent 1 or 2 independently, and more preferably m and p represent 1.

In a preferred embodiment, m represents 2 and two R²Base is interconnected to form the C-2 of connection piperazine ring and the CH of C-5₂Base.

When A represents-Ar¹During base, Ar¹Optional substituted phenyl of preferred expression or pyridyl, the more preferably optional phenyl that is replaced by halogen (for example, chlorine, fluorine or bromine), cyano group, trifluoromethyl or trifluoromethoxy of expression.Particularly preferred Ar¹Be unsubstituted phenyl or the phenyl that replaced by following substituting group: halogen (for example, 2-chlorine, 3-chlorine, 4-chlorine, 2-fluorine, 3-fluorine, 4-fluorine or 4-bromine), C_1-6Alkyl (for example, 2-methyl or 4-methyl), C_1-6Alkoxyl group (for example, 2-methoxyl group), trifluoromethyl (for example, 2-trifluoromethyl or 3-trifluoromethyl) or trifluoromethoxy (for example, 2-trifluoromethoxy).

When A represents-Ar²-Ar³During base, Ar²And Ar³Preferably represent phenyl or bicyclic heteroaryl as defined above independently.

Preferred A represents-Ar¹Base.

Most preferred-Ar¹It is unsubstituted phenyl.

Preferred compound of the present invention or its pharmacologically acceptable salt comprise the compound of following embodiment E 1-E50.

Formula (I) compound can form its acid salt.Should be understood that when being used for medicine, the salt of formula (I) compound should be its pharmacologically acceptable salt.Suitable pharmacologically acceptable salt will be apparent to those skilled in the art, and be included in J.Pharm.Sci., 1977,66, disclosed pharmacologically acceptable salt among the 1-19, for example, with mineral acid (as, hydrochloric acid, Hydrogen bromide, sulfuric acid, nitric acid or phosphoric acid) and with organic acid (as, Succinic Acid, toxilic acid, acetate, fumaric acid, tartrate, phenylformic acid, tosic acid, methylsulfonic acid or naphthene sulfonic acid) acid salt that forms.Within the scope of the present invention, the present invention includes all possible stoichiometry and nonstoichiometry acid salt.

Formula (I) compound can crystallized form or the preparation of noncrystalline form, if with crystallized form preparation formula (I) compound, then its can to choose wantonly be solvate, for example, be the form of hydrate.Within the scope of the present invention, the compound that the present invention includes stoichiometry solvate (for example, hydrate) and contain variable quantity solvent (for example, water).

Some formula (I) compound can exist with steric isomer (for example, diastereomer and enantiomorph), and the present invention includes its various steric isomers and composition thereof, comprises racemoid.With ordinary method different heterogeneous types are separated from each other, perhaps, can make any specified isomer by stereospecific synthesis or asymmetric synthesis.The present invention also comprises any tautomer and its mixture.

The preferred compound of the present invention comprises 3-benzenesulfonyl-8-piperazine-1-yl-quinoline or its pharmacologically acceptable salt (for example, hydrochloride), most preferably its free alkali (for example, 3-benzenesulfonyl-8-piperazine-1-yl-quinoline).

Have now found that the polymorphic that 3-benzenesulfonyl-8-piperazine-1-yl-quinoline free alkali exists surpasses a kind of.The present invention includes all these polymorphics, can be that pure polymorphic also can be and any other material such as another kind of polymorphic blended polymorphic.In the present invention, the polymorphic with free alkali is called I type and II type.Depend on the circumstances, in the present invention, described various polymorphics also can be called free alkali.

Correspondingly, the invention provides free alkali, and the data that provide by following at least a analytical procedure suitably characterize: infrared spectra provided by the invention, Raman spectrum, X-ray powder diffraction or nucleus magnetic resonance and fusing point data comprise part spectroscopic data provided by the invention.

On the other hand, the invention provides I type 3-benzenesulfonyl-8-piperazine-1-yl-quinoline.

Another aspect the invention provides II type 3-benzenesulfonyl-8-piperazine-1-yl-quinoline.

Particularly, the invention provides 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (I type), it is characterized by:

(i) with the infrared spectra of Fig. 1 basically identical; And/or

(ii) with the Raman spectrum of Fig. 2 basically identical; And/or

(iii) scheme with the X-ray powder diffraction (XRPD) of Fig. 3 basically identical.

Particularly, the invention provides 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (II type), it is characterized by:

(i) with the infrared spectra of Fig. 4 basically identical; And/or

(ii) with the Raman spectrum of Fig. 5 basically identical; And/or

(iii) scheme with the X-ray powder diffraction (XRPD) of Fig. 6 basically identical.

Because the higher feasible stability of fusing point is higher, therefore, 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (II type) is the preferred polymorphic of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline.

The present invention also provides the preparation method of formula (I) compound or pharmaceutically acceptable salt thereof, and this method comprises:

(a) with formula (II) compound,

Wherein, R^1aThe same R of definition¹Or the N-protected base, R², R³, R⁴, R⁵, m, n and p the same and L of definition¹It is leavings group such as iodine or trifluoro-methanesulfonyl oxy; With formula A-SO₂H compound reaction (or with A-SH reaction, carry out oxidation step then), wherein the definition of A is the same, sloughs R then where necessary^1aThe N-protected base;

(b) with protected formula (I) compound deprotection, and optional subsequently

(c) change is other formula (I) compound and/or forms pharmacologically acceptable salt and/or solvate.

The present invention also provides the another kind of preparation method of formula (I) compound or pharmaceutically acceptable salt thereof, and this method comprises:

(d) with formula (IV) compound

With the reaction of formula V compound,

Wherein, R^1a, R², R³, R⁴, R⁵, A, m, n and p the same and L of definition²The suitable leavings group of expression such as halogen atom then, is sloughed R in case of necessity^1aThe N-protected base; Or

(e) with formula (VI) compound

With the reaction of formula (VII) compound,

Wherein, R^1a, R², R³, R⁴, R⁵, A, m, n and p the same and L of definition³The suitable leavings group of expression such as halogen atom (as, bromine or iodine atom) or trifluoro-methanesulfonyl oxy then, is sloughed R in case of necessity^1aThe N-protected base.The N-protected base that uses can be any conventional group, for example, and tert-butoxycarbonyl (Boc) or benzyloxycarbonyl.Operable other N-protected base comprises methyl.

Make formula (II) compound and formula A-SO₂The step (a) of H compound reaction generally includes the use alkaline condition, and, such as N, in the suitable solvent of dinethylformamide, in the presence of transition metal salt, by use compd A-SO such as cupric iodide (I)₂The acceptable acid addition salts of H (for example, sodium salt) can be carried out this step (a) the most expediently.

Make the step (a) of formula (II) compound and formula A-SH compound reaction generally include the use alkaline condition, for example, such as N, in the suitable solvent of dinethylformamide, in the presence of suitable metal salt, use the acceptable acid addition salts (for example, sodium salt) of compd A-SH such as cupric iodide (I), then, the suitable oxidizers of use such as 3-chlorine peroxybenzoic acid, peracetic acid or potassium hydrogen persulfate.

In step (a) with (b), the method for the example of protecting group and deprotection base can be referring to T.W.Greene " Protective Groups in Organic Synthesis " (J.Wiley and Sons, 1991).Suitable amine protecting group comprises that alkylsulfonyl (for example; tosyl group), acyl group (for example, ethanoyl, 2 ', 2 '; 2 '-trichlorine ethoxy carbonyl, benzyloxycarbonyl or tert-butoxycarbonyl) and aralkyl is (for example; benzyl), depend on the circumstances, described protecting group can be by hydrolysis (for example; use the acid of all example hydrochloric acids) or reduction is (for example; the hydrogenolysis benzyl or in acetate with zinc reduction remove 2 ', 2 ', 2 '-the trichlorine ethoxy carbonyl) slough.Other suitable amine protecting group comprises trifluoroacetyl group (COCF₃) (it can be removed by alkali catalyzed hydrolysis) or solid-phase resin bonded benzyl, as 2 of Merriffield resin-bonded, 6-dimethoxy-benzyl (Ellman linker), it can be removed by acid-catalyzed hydrolysis, for example, uses trifluoroacetic acid.Another kind of amine protecting group comprises methyl, and it can remove (for example, use chloroformic acid 1-chloroethene ester under alkaline condition, handle with methyl alcohol then) by the standard method of N-dealkylation.

Step (c) can adopt conventional change method to carry out, for example, and epimerization, oxidation, reduction, reductive alkylation, alkylation, nucleophilic or electrophilic aromatic substitution, esterlysis or formation amido linkage.For example, with R¹Formula (I) compound N-dealkylation of expression alkyl obtains wherein R¹Formula (I) compound of expression hydrogen.Be understandable that this change can be the change of protected formula (I) derivative, after change, can be with formula (I) derivative deprotection.

In addition, step (c) can comprise, for example, in the presence of reductive agent, incites somebody to action wherein R¹Formula (I) compound of expression hydrogen and aldehydes or ketones reaction are to make wherein R¹Expression C_1-6The formula of alkyl (I) compound.This can carry out as follows: in such as the alcoholic acid alcoholic solvent, in the presence of acid such as acetate, the hydride of use such as cyano group sodium borohydride, triacetyl oxygen base sodium borohydride or resin mating-type cyano group borohydride carries out this reaction for body reagent, perhaps, under the shortening condition, carry out this reaction.Perhaps, use such as N dinethylformamide or C_1-4The suitable solvent of alkanol is chosen wantonly in the presence of the appropriate base such as salt of wormwood or triethylamine, passes through R¹Formula (I) compound and the formula R of expression hydrogen¹-L compound reacts and carries out this conversion, wherein R¹The same and L of definition represent leavings group such as halogen atom (for example, bromine or iodine) or mesyloxy.

Step (d) can be in the presence of the appropriate base such as yellow soda ash, use the suitable solvent such as propyl carbinol to carry out.

Step (e) can be at palladium, nickel or copper catalyst (for example, such as Pd₂(dba)₃The palladium source with such as (R)-, (S)-or (±)-2,2 '-two (diphenylphosphino)-1,1 '-dinaphthalene (BINAP) or (2-dicyclohexyl phosphanyl phenyl)-dimethylamine or 1,1 '-mixture of the suitable ligand of two-diphenylphosphino ferrocene) and exist down such as the appropriate base of sodium tert-butoxide, such as 1, carry out in the inert solvent of 4-dioxane.

With formula (III) compound,

Wherein, R³, R⁴, R⁵, n and L¹Define the samely,, can make formula (II) compound with above-mentioned formula (IV) compound reaction.This method generally includes the appropriate base of use such as yellow soda ash and the suitable solvent of use such as the trimethyl carbinol.

The formula V compound can make by following reaction scheme:

Wherein, R³, R⁴, R⁵, n, A and L¹Define the same.

Step (i) generally comprises: in the presence of copper (I) salt such as copper trifluoromethanesulfcomposite (I) or cupric iodide (I), such as anhydrous N, dinethylformamide or 1, in the suitable solvent of 4-dioxane, optional comprising such as N, N '-dimethyl-ethylidene-1, the part of 2-diamines makes formula (VIII) compound and formula A-SO₂-M compound reaction, wherein the same and M of A definition is the metal ion such as sodium or potassium.

Perhaps, the conversion reaction shown in the step (i) can use generally comprise step (iii) and two-step reaction method (iv) carry out.

Step (iii) generally comprises: in the presence of the alkali such as sodium hydride or potassiumphosphate, such as anhydrous N, in the suitable solvent of dinethylformamide or ethylene glycol, choose wantonly in the presence of cupric iodide (I) catalyzer, make the reaction of formula (VIII) compound and formula A-SH compound, wherein the A definition is the same.

Step (iv) generally includes the oxidizing reaction of the suitable oxidizers of use such as peroxide phthalic acid one magnesium, 3-chlorine peroxybenzoic acid, peracetic acid or potassium hydrogen persulfate.

Step (ii) generally includes the use appropriate reductant, and for example titanium chloride (III) or iron powder are in proper solvent system, as respectively in tetrahydrofuran aqueous solution and/or acetate.

Can make L according to following reaction scheme³Formula (VI) compound of expression halogen atom:

Wherein, R³, R⁴, R⁵, n and A definition is the same, Hal represents halogen atom.

Step (i) generally comprises with currently known methods (for example carries out diazotization, use Sodium Nitrite and use inorganic acid aqueous solution as solvent, perhaps use alkyl nitrite, and the suitable solvent of use such as acetonitrile, in the presence of anhydrous acid such as trifluoroacetic acid), then, with suitable halogen, as cupric bromide (I), potassiumiodide or tetrabutylammonium iodide, handle resulting diazonium salt.Said process can carry out in the aqueous solution or carry out under anhydrous condition, for example, uses trifluoroacetic acid as solvent.

Also can make L according to following reaction scheme³Formula (VI) compound of expression halogen atom:

Wherein, R³, R⁴, R⁵, A and n definition the same, Hal represents halogen atom.

The suitable reductive agent that step (i) generally includes use such as iron powder makes formula (XI) compound.

Step (ii) generally includes uses aforesaid nitrous  deionized water solution or non-aqueous solution to carry out diazotization reaction, changes into halogenide then.

Step (iii) generally includes the suitable oxidizers of use such as peroxide phthalic acid one magnesium.

Carry out diazotization by above-mentioned formula V compound according to currently known methods, under acidic conditions, heat then, in the presence of alkali, handle again, can make formula (VI) compound that L3 represents trifluoro-methanesulfonyl oxy with trifluoromethanesulfanhydride anhydride such as pyridine.

Formula (III), (IV), (VII) and (VIII) compound be the known compound in the document or can make according to similar approach.

Usually, pharmacologically acceptable salt can be by making with suitable acid or acid derivative reaction.

Formula (I) compound and its pharmacologically acceptable salt are to 5-HT₆Acceptor has affinity, and think that they are such as anxiety, dysthymia disorders, epilepsy, idea and behavior obsession, migraine, cognitive dysmnesia (for example, Alzheimer's, cognitive decline relevant and slight cognitive impairment) with the age, Parkinson's disease, ADHD (attention damaged/superfunction syndrome), somnopathy (comprising circadian rhythm disorder), pickuping food obstacle (as apocleisis and Bulimia nerovsa), panic attack, withdrawal is such as Cocaine, alcohol, the drug abuse of Nicotine and benzodiazepines class, schizophrenia (the particularly cognitive impairment in the schizophrenia), apoplexy and with spinal trauma and/or head infringement (as, hydrocephalus) diseases associated treatment in potential use is arranged.Estimate that also The compounds of this invention can be used for some GI (stomach and intestine) disease of treatment such as IBS (irritable bowel syndrome).It is fat to estimate that The compounds of this invention also can be used for treatment.

Therefore, the present invention also provides as therapeutant, particularly treats or prevent formula (I) compound or pharmaceutically acceptable salt thereof of above-mentioned disease.Particularly, the invention provides formula (I) compound or pharmaceutically acceptable salt thereof that is used for the treatment of following disease: cognitive impairment and apoplexy in dysthymia disorders, anxiety, Alzheimer's, the cognitive decline relevant, ADHD, obesity, slight cognitive impairment, schizophrenia, the schizophrenia with the age.

The present invention also provides treatment or prevention to comprise the method for human mammiferous above-mentioned disease, comprises formula (I) compound or pharmaceutically acceptable salt thereof to patient's drug treatment significant quantity.

On the other hand, the invention provides formula (I) compound or pharmaceutically acceptable salt thereof in preparation treatment or prevent purposes in the medicine of above-mentioned disease.

As described in International Patent Application PCT/EP03/00462,5-HT₆Antagonist has the possibility that can improve the how sialylated neurocyte frequency of brain (as temporal lobe in the middle of, the rat and associating hippocampus) basis and study inductive.Therefore, according to a further aspect in the invention, we provide the method that promotes the neure growth in the mammalian central nervous system, and this method comprises the step of Medicine-feeding type (I) compound or pharmaceutically acceptable salt thereof.

For use formula (I) compound in treatment, generally use the standard pharmaceutical technology that it is mixed with pharmaceutical composition.The present invention also provides a kind of pharmaceutical composition that comprises formula (I) compound or pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.

Can be by mixing, that the pharmaceutical composition of the present invention that suits to prepare under normal temperature and normal pressure is generally suitable for is oral, parenteral or rectal administration, therefore, but can be tablet, capsule, oral liquid, pulvis, granula, lozenge, the pulvis that can prepare again, injectable or infusion solution or suspension or suppository.General preferred oral administration composition.

The tablet of oral administration and capsule can be unit dosage, and can contain conventional excipient, for example, and tackiness agent, filler, compressing tablet lubricant, disintegrating agent and pharmaceutically acceptable wetting agent.Can be according to the currently known methods in the standard pharmaceutical technology with tablet coating.

Oral liquid can be, for example, water-based or oily suspensions, solution, emulsion, syrup or elixir perhaps can be the dry labor things, and water or other suitable excipient are prepared again before use for they.This liquid preparation can contain conventional additives, for example, and suspension agent, emulsifying agent, non-water excipient punishment (can comprise edible oil), sanitas, and, if desired, conventional seasonings or tinting material.

For administered parenterally, use The compounds of this invention or its pharmacologically acceptable salt and aseptic excipient to prepare the liquid unit dosage.According to excipient and the concentration used, compound can be suspended or is dissolved in the excipient.In the preparation of solution,, compound dissolution and filtration sterilization can be injected suitable bottle or ampoule and sealing then in order to inject.It is favourable will being dissolved in such as the assistant agent of local anesthetic, sanitas and buffer reagent in the excipient.In order to improve stability, in being injected into bottle after, can frozen composition, and vacuum is removed and anhydrated.Prepare parenteral suspension by substantially the same method, but be not with compound dissolution in excipient, and replace compound is suspended in the excipient, and can not be by filter realizing sterilization.Before compound is suspended in aseptic excipient, it is exposed among the oxyethane, can realize sterilization.In composition, contain and to promote that equally distributed tensio-active agent of compound or wetting agent are favourable.

According to medication, composition can contain 0.1%-99 weight % active substance, preferably contains 10-60 weight % active substance.

The dosage that is used for the treatment of the compound of above-mentioned disease changes with disease severity, weight in patients and other similar factor usually.Yet usually, proper dosage can be 0.05-1000mg, is preferably 0.05-200mg, for example, and 20-40mg; And, the above-mentioned unitary dose that is administered once preferred every day, but may need administration every day to surpass once; And this treatment can continue several weeks or several months.

All documents of quoting in this specification sheets (including but not limited to patent and patent application) document incorporated by reference is in the present invention drawn in full and is made reference of the present invention as specifically and separately indicating every piece of document.

Following explanation and embodiment have illustrated the preparation of The compounds of this invention for example.

Illustrate 1

3-bromo-8-(4-methyl-piperazine-1-yl)-quinoline (D1)

Will two-(2-chloro-ethyl)-amine hydrochlorate (3.7g, 19.2mmol) and yellow soda ash (9.0g 85mmol) joins the basic amine (3.9g of 3-bromo-quinoline-8-, 17.5mmol) (it is synthetic referring to Gershon etc., Monatsh.Chem., 1991,122,935) in propyl carbinol (70ml) suspension.With the suspension reflux that stirring 72 hours.Reaction mixture is to room temperature, with methylene dichloride (300ml) dilution, water (300ml) washing soln, dry (MgSO₄), vacuum concentration becomes oily matter.On silica gel,, carry out gradient elution, obtain oily title compound (D1) (2.6g, 8.5mmol, 49%) with ethanol/methylene by this oily matter of chromatographic purification;

δ_H(CDCl₃)2.43(3H，s)，2.78(4H，br s)，3.44(4H，br，s)，7.14(1H，d，J＝6.8Hz)，7.33(1H，d，J＝7.4Hz)，7.47(1H，dd，J＝7.8Hz)，8.25(1H，d，J＝2.3Hz)，8.85(1H，d，J＝2.3Hz).

Mass spectrum: C₁₄H₁₆BrN₃Theoretical value: 305/307; Measured value: 306/308 (MH⁺).

Illustrate 2

3-iodo-8-(4-methyl-piperazine-1-yl)-quinoline (D2)

Under argon gas atmosphere, in 150 ℃ of oil baths, with 3-bromo-8-(4-methyl-piperazine-1-yl)-quinoline (D1) (1.75g, 5.7mmol), cupric iodide (I) (5.4g, 28.5mmol) and potassiumiodide (9.6g, 57.8mmol) mixture heating up in hexamethylphosphoramide (20ml) is 21 hours.In the refrigerative reaction mixture, add toluene (120ml) and 1M hydrochloric acid (120ml), and it was acutely swayed 5 minutes.Then, filter and collect insoluble brown solid, (3 * 40ml) wash, and are suspended in again in the mixture of methylene dichloride (150ml) and 2M sodium hydroxide (150ml) with methyl alcohol.After acutely swaying mixture, filter out insolubles, with methylene dichloride (2 * 50ml) and discard.Be transferred in the separating funnel filtrate and washings and layering.The water methylene dichloride (2 * 100ml) extractions, and with the organic extract liquid drying (MgSO that merges₄), concentrate and obtain brown oil (1.5g), by the NMR wave spectrum, determine that it is 4: 1 mixtures of title compound (D2) and 3-bromo-8-(4-methyl-piperazine-1-yl)-quinoline (D1).This mixture is directly used in next step (referring to embodiment 1).

3-iodo-8-(4-methyl-piperazine-1-yl)-quinoline (D2): δ_H(CDCl₃) 2.41 (3H, s), 2.76 (4H, br s), 3.42 (4H, br s), 7.14 (1H, d, J=6.8Hz), 7.29 (1H, d, J=7.4Hz), 7.44 (1H, dd, J=7.8Hz), 8.47 (1H, d, J=2.3Hz), 8.98 (1H, d, J=2.3Hz);

Mass spectrum: C₁₄H₁₆IN₃Theoretical value: 353; Measured value: 354 (MH⁺).

Illustrate 3

3-iodo-8-nitroquinoline (D3)

(100g, 0.57mol) (155g 0.69mol) handled 10 minutes the N-iodo succimide that adds with gradation with the mixture of acetate (500ml), and 62 ℃ ofheating 6 hours with the 8-nitroquinoline that stirs.(25g, 0.14mol),restir mixture 16 hours is cooled to room temperature then to add another part N-iodo succimide.Keep temperature to be lower than 35 ℃, solvent removed in vacuo.Resistates is dissolved in the methylene dichloride (2L), uses E and sodium bicarbonate aqueous solution (2 * 1L), 10% sodium thiosulfate solution (1L), water (1L), salt solution (100ml) washing, organic phase dried over mgso successively.Mixture is filtered, remove and desolvate, obtain yellow solid,, obtain yellow solid title compound (D3) (168g, 97%) this yellow solid recrystallization from ethyl acetate;

δ_H(CDCl₃)7.65(1H，app.t)，7.94(1H，dd)，8.07(1H，dd)，8.66(1H，d，J＝2Hz)，9.19(1H，d，J＝2Hz)；

Mass spectrum: C₉H₅IN₂Theoretical value: 300; Measured value: 301 (MH⁺).

Illustrate 4

8-nitro-3-benzenesulfonyl quinoline (D4)

Under argon gas atmosphere, be equipped with in the 5L three-necked flask of agitator at the top, (135g 0.45mol) is suspended in the dimethyl formamide (2.4L) with 3-iodo-8-nitroquinoline (D3).Mixture is used anhydrous Sodium phenylsulfinate (99.6g 0.608mol) and two-(copper trifluoromethanesulfcomposite (I)) benzene complex successively, and (170g 0.338mol) handles.The slurry that obtains was heated 18 hours at 65 ℃.Cooling mixture filters and vacuum evaporating solvent.In resistates, add acetone (2.5L), and filtering solution.Vacuum-evaporation filtrate adds 2.5L acetone again, refilters mixture.Vacuum evaporating solvent is dissolved in resistates in the chloroform (3L), and (2 * 2L) washings, organic phase is with dried over mgso and vacuum evaporating solvent with 10% ammoniacal liquor.The Vandyke brown resistates with hexane and the eluent ethyl acetate that increases progressively ratio, obtains yellow solid title compound (D4) (81.5g, 58%) with Biotage-150 chromatographic instruments (5kg silica gel) purification fast;

δ_H(d6-DMSO)7.67(2H，t)，7.57(1H，d，7.96(1H，t)，8.13(2H，d)，8.51(1H，d)，8.59(1H，d)，9.42(1H，d)，9.50(1H，d)；

Mass spectrum: C₁₅H₁₀SO₄N₂Theoretical value: 314; Measured value: 315 (MH⁺).

Illustrate 5

8-amino-3-benzenesulfonyl quinoline (D5)

To keep temperature to be lower than 35 ℃ speed; will be at the 8-nitro in the tetrahydrofuran (THF) (750ml)-3-benzenesulfonyl quinoline (D4) (46.7g; slurries 172mmol) join in 30% titanium chloride (III) solution [being provided by BDH] in the HCl aqueous solution (470ml), and described titanium chloride (III) solution cools off in ice bath and stirs.Finish in case add,restir solution 10 minutes adds entry (1.5L) then, and with in the mixture impouring 5L beaker.Gradation adds potash solid, and to handle the solution of quick stirring, making its pH is about 8.5.(250g, 0.86mol), and then adding salt of wormwood, to keep its pH be about 8.5 to add EDTA.(3 * 1L) extract mixture, and the organic phase that makes merging is by silica filler (500g), with methylene dichloride (1L) eluant solution of methylene dichloride (1L) and 10% ethyl acetate with methylene dichloride.The organic phase that evaporation merges, resistates with methylene dichloride and the ether wash-out that increases progressively ratio, obtains light brown solid title compound (D5) (34.5g, 72%) with Biotage-75 chromatographic instruments (2kg silica gel) purification fast;

δ_H(CDCl₃)5.0(2H，br s)，7.02(1H，dd)，7.25(1H，dd)，7.44(1H，t)，7.50-7.59(3H，m)，8.00-8.40(2H，m)，8.70(1H，s)，0.09(1H，s)；

Mass spectrum: C₁₅H₁₂SO₂N₂Theoretical value: 284; Measured value: 285 (MH⁺).

Illustrate 6

8-iodo-3-benzenesulfonyl quinoline (D6)

(31.6g 0.11mol) is dissolved in the trifluoroacetic acid (60ml) and evaporating mixture with 8-amino-3-benzenesulfonyl quinoline (D5).The brown oil that obtains is dissolved in the acetonitrile (200ml), and drops in acetonitrile (300ml) solution of nitrous acid straight butyl (6.1ml) of stirring, keep solution temperature＜5 ℃.In case finish dropping, stirred themixture 5 minutes, then, keep temperature to be lower than 10 ℃, add in batches iodate tetra-n-butyl ammonium (82g, 0.22mol).Restir mixture 20 minutes, vacuum concentration then.Dark resistates with hexane and methylene dichloride wash-out, obtains brown solid with-75 chromatographic instruments (2kg silica gel) purification fast.It is dissolved in the methylene dichloride (500ml), and (2 * 300ml) washings with dried over mgso and concentrated, obtain orange solids with 10% sodium thiosulfate solution.It is developed with methyl alcohol, obtain light yellow solid title compound (D6) (25.2g, 75%);

δ_H(CDCl₃)7.39(1H，t)，7.53-7.63(3H，m)，7.96(1H，d)，8.04(2H，dd)，8.50(1H，dd)，8.79(1H，d)，9.32(1H，d)；

Mass spectrum: C₁₅H₁₀NO₂SI theoretical value: 395; Measured value: 396 (MH⁺).

Illustrate 7

8-(4-tert-butoxycarbonyl) piperazine-1-base-3-benzenesulfonyl quinoline (D7)

Under argon gas atmosphere, (25.2g 63.6mmol) is dissolved in the no water degasification dioxane (500ml) with 8-iodo-3-benzenesulfonyl quinoline (D6).(8.56g, 89.2mmol) (14.2g 76.4mmol), then, under argon gas atmosphere, adds catalyst suspension with 1-tert-butoxycarbonyl piperazine to add sodium tert-butoxide in this solution.Catalyzer is by with three-(dibenzalacetone) two palladiums (0) (1.75g, 1.91mmol) and 2-dicyclohexyl phosphino--2 '-(N, the N-dimethylamino) (2.25g, 5.73mmol) the mixture sonication in no water degasification dioxane (10ml) made biphenyl in 2 minutes.Mixture was stirred 5 hours at 40 ℃, and then add catalyzer (make as stated above, its amount reduces by half), and 40 ℃ of continuously stirring 16 hours.

Filtering mixt also removes and desolvates.Resistates is adsorbed onto on the silicon-dioxide, and purifies,, obtain yellow solid title compound (D7) (22.0g, 76%) with the dichloromethane solution wash-out of 1% methyl alcohol in the enterprising circumstances in which people get things ready for a trip spectrum of silicon-dioxide;

δ_H(CDCl₃)1.49(9H，t)，3.31(4H，m)3.72(4H，m)，7.25(1H，m)，7.52(2H，t)7.57(3H，m)8.00(2H，m)8.76(1H，d)9.21(1H，d)；

Mass spectrum: C₂₄H₂₇N₃O₄S theoretical value: 453; Measured value: 454 (MH⁺).

Illustrate 8

8-(4-tert-butoxycarbonyl) piperazine-1-base-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D8)

Method by being similar to explanation 7 (D7) makes this compound by 8-iodo-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D34);

δ_H(CDCl₃)1.50(9H，s)，3.32(4H，t)，3.73(4H，t)，7.28(1H，d)，7.59(1H，s)，7.61(1H，d)，7.69(1H，t)，7.85(1H，d)，8.21(1H，d)，8.28(1H，s)，8.79(1H，d)，9.23(1H，s)；

Mass spectrum: C₂₅H₂₆F₃N₃O₄S theoretical value: 521; Measured value: 522 (MH⁺).

Illustrate 9

The high piperazine of 8-(4-tert-butoxycarbonyl)-1-base-3-benzenesulfonyl quinoline (D9)

Use 8-iodo-3-benzenesulfonyl quinoline (D6) (200mg, 0.51mmol), sodium tert-butoxide (68mg, 0.71mmol), the high piperazine of 1-(tert-butoxycarbonyl) (122mg, 0.61mmol),

Three-(dibenzalacetone) two palladiums (0) (14mg, 0.015mmol) and 2-dicyclohexyl phosphino--2 '-(18mg 0.045mmol), makes this compound by the method that is similar to explanation 7 (D7) to (N, N-dimethylamino) biphenyl.What aforesaid method obtained is the mixture that contains title compound (D9).With this mixture cooling, filter and evaporating solvent, and crude product is directly used in embodiment 14 (E14);

Mass spectrum: C₂₅H₂₉N₃O₄S theoretical value: 467; Measured value: 468 (MH⁺).

Illustrate 10

8-amino-3-(2-chlorine) benzenesulfonyl quinoline (D10)

Method by being similar to explanation 5 (D5) makes this compound by 3-(2-chlorine) benzenesulfonyl-8-nitro-quinoline (D18);

δ_H(CDCl₃)5.0(2H，br s)，7.07(1H，d)，7.27(1H，d)，7.43-7.47(2H，m)，7.52-7.57(2H，m)，8.44-8.46(1H，m)，8.77(1H，d)，9.05(1H，d)；

Mass spectrum: C₁₅H₁₁ClN₂O₂S theoretical value: 318,320; Measured value: 319,321 (MH⁺).

Illustrate 11

8-amino-3-(3-chlorine) benzenesulfonyl quinoline (D11)

Method by being similar to explanation 5 (D5) makes this compound by 3-(3-chlorine) benzenesulfonyl-8-nitro-quinoline (D19);

δ_H(CDCl₃)5.0(2H，br s)，7.05(1H，d)，7.27(1H，d)，7.43-7.57(3H，m)，7.89(1H，d)，8.00(1H，t)，8.70(1H，d)，9.08(1H，d)；

C₁₅H₁₁ClN₂O₂S theoretical value: 318,320; Measured value: 319,321 (MH⁺).

Illustrate 12

8-amino-3-(2-fluorine) benzenesulfonyl quinoline (D12)

Method by being similar to explanation 5 (D5) makes this compound by 3-(2-fluorine) benzenesulfonyl-8-nitro-quinoline (D20);

δ_H(CDCl₃)5.1(2H，br s)，7.08(2H，t)，7.27(1H，d)，7.36(1H，t)，7.46(1H，m)，7.55-7.63(1H，m)，8.19(1H，t)，8.79(1H，t)，9.14(1H，t)；

Mass spectrum: C₁₅H₁₁FN₂O₂S theoretical value: 302; Measured value: 303 (MH⁺).

Illustrate 13

8-amino-3-(4-chlorine) benzenesulfonyl quinoline (D13)

Method by being similar to explanation 5 (D5) makes above-claimed cpd by 3-(4-chlorine) benzenesulfonyl-8-nitro-quinoline (D21);

δ_H(CDCl₃)5.0(2H，br s)，7.05(1H，dd)，7.25(1H，dd)，7.42-7.53(3H，m)，7.95(2H，dt)，8.68(1H，d)，9.07(1H，s)；

Mass spectrum: C₁₅H₁₁N₂SO₂Cl theoretical value: 318,320; Measured value: 319,321 (MH⁺).

Illustrate 14

8-amino-3-(3-fluorine) benzenesulfonyl quinoline (D14)

Method by being similar to explanation 5 (D5) makes this compound by 3-(3-fluorine) benzenesulfonyl-8-nitro-quinoline (D22);

δ_H(CDCl₃)5.0(2H，br s)，7.05(1H，dd)，7.24-7.29(2H，m)，7.44(1H，d)，7.52(1H，dt)，7.72(1H，dt)，7.82(1H，dt)，8.70(1H，d)，9.09(1H，d)；

Mass spectrum: C₁₅H₁₁N₂O₂SF theoretical value: 302; Measured value: 303 (MH⁺).

Illustrate 15

8-amino-3-(4-bromo-2-trifluoromethoxy) benzenesulfonyl quinoline (D15)

Method by being similar to explanation 5 (D5) makes this compound by 3-(4-bromo-2-trifluoromethoxy) phenyl-8-nitro-alkylsulfonyl quinoline (D23);

δ_H(CDCl₃)5.0(2H，br s)，7.07(1H，dd)，7.26(1H，dd)，7.43-7.48(2H，m)，7.65(1H，dd)，8.21(1H，d)，8.72(1H，d)，9.04(1H，d)；

Mass spectrum: C₁₆H₁₀N₂O₃SF₃Br theoretical value: 446,448; Measured value: 447,449 (MH⁺).

Illustrate 16

8-amino-6-methyl-3-benzenesulfonyl quinoline (D16)

Method by being similar to explanation 5 (D5) makes this compound by 6-methyl-8-nitro-3-benzenesulfonyl quinoline (D24);

δ_H(CDCl₃)2.45(3H，s)，4.94(2H，br s)，6.90(1H，s)，7.04(1H，s)，7.50-7.60(3H，m)，8.02(2H，d)，8.60(1H，s)，9.01(1H，s)；

Mass spectrum: C₁₆H₁₄N₂O₂S theoretical value: 298; Measured value: 299 (MH⁺).

Illustrate 17

8-amino-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D17)

Method by being similar to explanation 5 (D5) makes this compound by 8-nitro-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D25);

δ_H(CDCl₃)5.0(2H，br s)，7.06(1H，dd)，7.27(1H，d)，7.47(1H，t)，7.69(1H，t)，7.85(1H，d)，8.20(1H，d)，8.29(1H，s)，8.73(1H，d)，9.10(1H，d)；

Mass spectrum: C₁₆H₁₁N₂O₂SF₃Theoretical value: 352; Measured value: 353 (MH⁺).

Illustrate 18

3-(2-chlorine) benzenesulfonyl-8-nitro-quinoline (D18)

(0.63g, 2.0mmol) (1.73g, 10mmol) the mixture stirring at room in methylene dichloride (10ml) is 3 hours with 3-chlorine peroxybenzoic acid with 3-(2-chlorine) thiophenyl-8-nitro-quinoline (D26).Use methylene dichloride (50ml) diluted mixture thing then, with the saturated sodium metabisulfite aqueous solution (50ml) and saturated sodium bicarbonate aqueous solution (50ml) washing, dried over mgso and vacuum concentration obtain orange pasty state title compound (D18) (0.65g, 94%);

δ_H(CDCl₃)7.06(1H，d)，7.27(1H，d)，7.44(1H，s)，7.52-7.57(3H，m)，8.48(1H，d)，8.76(1H，d)，9.05(1H，d)；

Mass spectrum: C₁₅H₉ClN₂O₄S theoretical value: 348,350; Measured value: 349,351 (MH⁺).

Illustrate 19

3-(3-chlorine) benzenesulfonyl-8-nitro-quinoline (D19)

Method by being similar to explanation 18 (D18) makes this compound by 3-(3-chlorine) thiophenyl-8-nitro-quinoline (D27);

δ_H(CDCl₃)7.52(1H，t)，7.62(1H，d)，7.81(1H，t)，7.93(1H，d)，8.00(1H，s)，8.21-8.24(2H，m)，8.95(1H，d)，9.39(1H，d)；

Mass spectrum: C₁₅HClN₂O₄S theoretical value: 348,350; Measured value: 349,351 (MH⁺).

Illustrate 20

3-(2-fluorine) benzenesulfonyl-8-nitro-quinoline (D20)

Method by being similar to explanation 18 (D18) makes this compound by 3-(2-fluorine) thiophenyl-8-nitro-quinoline (D28);

δ_H(CDCl₃)7.17(1H，t)，7.40(2H，t)，7.65(1H，m)，7.81(1H，t)，8.20-8.27(2H，m)，9.05(1H，t)，9.40(1H，t)；

Mass spectrum: C₁₅H₉FN₂O₄S theoretical value: 332; Measured value: 333 (MH⁺).

Illustrate 21

3-(4-chlorine) benzenesulfonyl-8-nitro-quinoline (D21)

Method by being similar to explanation 18 (D18) makes this compound by 3-(4-chlorine) thiophenyl-8-nitro-quinoline (D29);

δ_H(CDCl₃)7.54(2H，dt)，7.80(1H，t)，7.97(2H，dt)，8.20(2H，d)，8.92(1H，d)，9.37(1H，d)；

Mass spectrum: C₁₅H₉N₂SO₄Cl theoretical value: 348,350; Measured value: 349,351 (MH⁺).

Illustrate 22

3-(3-fluorine) benzenesulfonyl-8-nitro-quinoline (D22)

Method by being similar to explanation 18 (D18) makes this compound by 3-(3-fluorine) thiophenyl-8-nitro-quinoline (D30);

Mass spectrum: C₁₅H₉N₂O₄SF theoretical value: 332; Measured value: 333 (MH⁺).

Illustrate 23

3-(4-bromo-2-trifluoromethoxy) phenyl-8-nitro-alkylsulfonyl quinoline (D23)

Method by being similar to explanation 18 (D18) makes this compound by 3-(4-bromo-2-trifluoromethoxy) thiophenyl-8-nitro-quinoline (D31);

Mass spectrum: C₁₆H₈N₂O₅SF₃Br theoretical value: 476,478; Measured value: 479,481 (MH⁺).

Illustrate 24

6-methyl-8-nitro-3-benzenesulfonyl quinoline (D24)

Method by being similar to explanation 18 (D18) makes this compound by 6-methyl-8-nitro-3-thiophenyl quinoline (D32);

δ_H(CDCl₃)2.65(3H，s)，7.60-7.67(3H，m)，7.95(1H，s)，8.00-8.05(3H，m)，8.82(1H，d)，9.30(1H，d)；

Mass spectrum: C₁₆H₁₂N₂O₄S theoretical value: 328; Measured value: 329 (MH⁺).

Illustrate 25

8-nitro-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D25)

Method by being similar to explanation 18 (D18) makes this compound by 8-nitro-3-(3-trifluoromethyl) thiophenyl quinoline (D33);

δ_H(CDCl₃)7.75(1H，t)，7.82(1H，t)，7.91(1H，d)，8.22-8.25(3H，m)，8.30(1H，s)，8.98(1H，d)，9.40(1H，d)；

Mass spectrum: C₁₆H₉N₂O₂SF₃Theoretical value: 381; Measured value: 382 (MH⁺).

Illustrate 26

3-(2-chlorine) thiophenyl-8-nitro-quinoline (D26)

(0.16g 6.67mmol) slowly adds 2-chlorothio-phenol (0.96g, dimethyl formamide 6.67mmol) (5ml) solution in the suspension in dimethyl formamide (10ml) to sodium hydride.Stirredreaction mixture 10 minutes, (1.0g, dimethyl formamide 3.33mmol) (5ml) solution was 90 ℃ ofheated mixt 4 hours slowly to add 3-iodo-8-nitroquinoline (D3) then.Cooling mixture carefully adds entry (50ml) to room temperature, and (2 * 50ml) extract mixtures with methylene dichloride.Organic phase is with salt solution (50ml) washing, through dried over mgso and vacuum concentration.Crude product is purified with silica gel chromatography, uses the hexane/ethyl acetate gradient elution, obtains brown oily title compound (D26) (0.70g, 70%);

δ_H(CDCl₃)7.25-7.28(1H，m)，7.34(1H，t)，7.40(1H，d)，7.51(1H，d)，7.63(1H，t)，7.93(1H，d)，8.02(1H，d)，8.09(1H，s)，8.87(1H，s)；

Mass spectrum: C₁₅H₉ClN₂O₂S theoretical value: 316,318; Measured value: 317,319 (MH⁺).

Illustrate 27

3-(3-chlorine) thiophenyl-8-nitro-quinoline (D27)

Method by being similar to explanation 26 (D26) makes this compound by 3-iodo-8-nitroquinoline (D3) and 3-chlorothio-phenol;

δ_H(CDCl₃)7.5(3H，br s)，7.45(1H，s)，7.63(1H，s)，7.92(1H，s)，8.02(1H，d)，8.10(1H，s)，8.89(1H，s)；

Mass spectrum: C₁₅H₉ClN₂O₂S theoretical value: 316,318; Measured value: 317,319 (MH⁺).

Illustrate 28

3-(2-fluorine) thiophenyl-8-nitro-quinoline (D28)

Method by being similar to explanation 26 (D26) makes this compound by 3-iodo-8-nitroquinoline (D3) and 2-fluoro thiophenol;

δ_H(CDCl₃)7.21(1H，d)7.42-7.49(2H，m)，7.53-7.62(2H，m)，7.88(1H，d)，7.97(1H，d)，8.04(1H，d)，8.86(1H，d)；

Mass spectrum: C₁₅H₉FN₂O₂S theoretical value: 300; Measured value: 301 (MH⁺).

Illustrate 29

3-(4-chlorine) thiophenyl-8-nitro-quinoline (D29)

Method by being similar to explanation 26 (D26) makes this compound by 3-iodo-8-nitroquinoline (D3) and 4-chlorothio-phenol;

δ_H(CDCl₃)7.00(1H，dd)，7.25-7.0(3H，m)，7.56(2H，d)，7.99(1H，dd)，8.24(1H，d)，8.81(1H，d)；

Mass spectrum: C₁₅H₉N₂O₂SCl theoretical value: 316,318; Measured value: 317,319 (MH⁺).

Illustrate 30

3-(3-fluorine) thiophenyl-8-nitro-quinoline (D30)

Method by being similar to explanation 26 (D26) makes this compound by 3-iodo-8-nitroquinoline (D3) and 3-fluoro thiophenol;

δ_H(CDCl₃)7.07(1H，dt)，7.15(1H，dt)，7.22(1H，dt)，7.35(1H，dd)，7.62(1H，dd)，7.94(1H，dd)，8.02(1H，dd)，8.11，(1H，d)，8.89(1H，d)；

Mass spectrum: C₁₅H₉N₂SO₂F theoretical value: 300; Measured value: 301 (MH⁺).

Illustrate 31

3-(4-bromo-2-trifluoromethoxy) thiophenyl-8-nitro-quinoline (D31)

Method by being similar to explanation 26 (D26) makes this compound by 3-iodo-8-nitroquinoline (D3) and 4-bromo-2-trifluoromethoxy thiophenol;

Mass spectrum: C₁₆H₈N₂O₃SF₃Br theoretical value: 444,446; Measured value: 445,447 (MH⁺).

Illustrate 32

6-methyl-8-nitro-3-thiophenyl quinoline (D32)

By the method that is similar to explanation 26 (D26), make this compound by 3-bromo-6-methyl-8-nitroquinoline [it is synthetic referring to Tinsley, J.Am.Chem.Soc., 1955,77,4175];

δ_H(CDCl₃)2.56(3H，s)，7.38-7.43(3H，m)，7.47-7.51(2H，m)，7.63(1H，s)，7.82(1H，s)，7.88(1H，d)，8.78(1H，d)；

Mass spectrum: C₁₆H₁₂N₂O₂S theoretical value: 296; Measured value: 297 (MH⁺).

Illustrate 33

8-nitro-3-(3-trifluoromethyl) thiophenyl quinoline (D33)

Method by being similar to explanation 26 (D26) makes this compound by 3-iodo-8-nitroquinoline (D3) and 3-trifluoromethyl thiophenol;

δ_H(CDCl₃)7.51(1H，t)，7.59-7.67(3H，m)，7.74(1H，br s)，7.94(1H，dd)，8.03(1H，dd)，8.13(1H，d)，8.90(1H，d)；

Mass spectrum: C₁₆H₉N₂SO₂F₃Theoretical value: 350; Measured value: 351 (MH⁺).

Illustrate 34

8-iodo-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D34)

By the method that is similar to explanation 6 (D6), make this compound with 44% yield by 8-amino-3-(3-trifluoromethyl) benzenesulfonyl quinoline (D17);

δ_H(CDCl₃)7.44(1H，t)，7.71(1H，t)，7.88(1H，d)，8.00(1H，dd)，8.22(1H，d)，8.29(1H，br s)，8.52(1H，dd)，8.1(1H，d)，9.33(1H，d)；

Mass spectrum: C₁₆H₉NO₂SIF₃Theoretical value: 463; Measured value: 464 (MH⁺).

General preparation method 1

Following intermediate is used to prepare the compound of embodiment 18-20,23-25,30,32-34 and 39.

4 (another kind of preparation methods) are described

8-nitro-3-benzenesulfonyl quinoline (D4)

In the 2L container, add 3-iodo-8-nitroquinoline (D3) (70.8g, 236mmol), cupric iodide (I) (2.25g, 11.8mmol, 5mol%), potassiumphosphate (100g, 472mmol, 2 equivalents), ethylene glycol (0.71L, 10 volumes) and benzenethiol (36.2ml, 354mmol).Mixture was 80 ℃ of stirring heating 3.5 hours.Reaction mixture to 20 ℃ adds H then₂O (700ml) and methylene dichloride (700ml).Stirred the mixture 5 minutes, and removed below organic layer (containing solid).Add charcoal (35.4g, Norit SX) to organic layer, in stirring at room mixture 15 minutes, then through the GF/F filter paper filtering.Filter cake methylene dichloride (140ml) rinsing, the filtrate of merging is used H₂O (350ml) washing.The dichloromethane solution that obtains was joined through 45 minutes in the suspension of Magnesium monoperoxyphthalate hexahydrate (210g, 424mmol, 1.8 equivalents) in methylene dichloride (700ml) and methyl alcohol (140ml) mixture, and remain on 18 ℃-23 ℃.Stirred the mixture fast 2.25 hours at 20-23 ℃, then with 15 minutes adding 10%w/v sodium sulfite aqueous solutions (700ml).Separating mixture, and handle with saturated sodium bicarbonate aqueous solution (280ml).Stirred the mixture layering 20 minutes.Remove the below organic layer, water (280ml) washing is concentrated into about 210ml under normal pressure.The mixture that obtains is cooled to 0 ℃, stirred 2 hours, filter then.Filter cake then 25-40 ℃ of vacuum-drying, obtains light yellow solid title compound (D4) with the 64-66% yield with cold (0-5 ℃) methylene dichloride (70ml) washing, and its spectrum is consistent with the spectrum of this compound for preparing with previous method.

Illustrate 35

8-amino-3-benzenesulfonyl quinoline mesylate (D35)

The suspension of iron powder (26.7g, 5 equivalents, 325 orders) in THF (300ml, 10 volumes), water (30ml, 1 volume) and acetate (19.2ml, 3.5 equivalents) is heated to 50 ℃.Keep temperature to be lower than 60 ℃, with added 8-nitro-3-benzenesulfonyl quinoline (D4) (30g, 1 weight) in 30 minutes in this mixture of clockwise in batches.50-55 ℃ of stirredreaction mixture 60 minutes.Add toluene (240ml, 8 volumes), add entry (60ml, 2 volumes), be cooled to 40 ℃ then, through the silica filler filtering mixt.With toluene (2 * 60ml, 2 volumes) washing silica filler.Isolate the filtrate layers of merging, with the organic layer vacuum concentration to about 10 volumes.Reacting by heating mixture to 77 ℃, then, keeping temperature is 75-80 ℃, with adding methylsulfonic acid (7.42ml, 1.2 equivalents) processing in 15 minutes.The orange suspension that obtains is slowly cooled to room temperature, in stirring at room about 2 hours, filtration product and with toluene (3 * 60ml) washings then.With resulting pink solid (D35) in about 45 ℃ of vacuum-dryings to weight.Yield: 34.7g, 94%.

δ_H(d6-DMSO) 2.46 (3H, s), 7.54 (1H, d, J=8Hz), 7.60-7.70 (3H, m), 7.70-7.75 (1H, t, J=8Hz), 7.81 (1H, J=8Hz), 8.13 (2H, d, J=8hz), 8.28 (3H, bs), 9.14 (1H, d, J=2Hz) and 9.28 (1H, J=2Hz).

6 (another kind of preparation methods) are described

8-iodo-3-benzenesulfonyl quinoline (D6)

Sodium Nitrite (5.44g, 78.8mmol, 1.2 equivalents) water (125ml, 5 volumes) solution is joined the 8-amino-3-benzenesulfonyl quinoline mesylate (D35) of stirring, and (25.0g is in 5MHCl 65.7mmol) (500ml, the 20 volumes) slurries.Stirred themixture 1hour 5 minutes at 23-24.5 ℃, add acetonitrile (200ml, 8 volumes) then.After 10 minutes,, obtain the brown mixture and emit gas with 3 minutes adding sodium iodide (14.8g, 98.6mmol, 1.5 equivalents) water (125ml, 5 volumes) solution.Stirred thebrown mixture 1hour 5 minutes at 25-23 ℃, add methylene dichloride (500ml, 20 volumes) then, stirred themixture 5 minutes.Remove the below organic layer and use methylene dichloride (125ml, 5 volumes) aqueous layer extracted.The machine layer that merges washs with 10%w/v S-WAT (125ml, 5 volumes), and concentrating under reduced pressure.The mixture that filtration obtains, filter cake with acetonitrile (2 * 25ml) washing and in 40 ℃ of baking ovens drying under reduced pressure, obtain title compound D6; Yield 15.27g, 59%, its spectrum is consistent with the spectrum of this compound for preparing with first method.

General preparation method 2

Following intermediate is used to prepare the compound of embodiment 21-22,26-29,31,35-38 and 40.

Illustrate 36

8-nitro-3-(3-fluorophenyl)-sulfenyl quinoline (D36)

With 3-iodo-8-nitroquinoline (D3) (4.5g, 15mmol), cupric iodide (I) (150mg, 0.8mmol, 5mol%), (2.88g, suspension 22.5mmol) stir and heated 3.5 hours down at 80 ℃ for potassiumphosphate (7.0g, 2 equivalents), ethylene glycol (45ml) and 3-fluorobenzene mercaptan.Reaction mixture is cooled to 20 ℃, adds H2O (45ml) and methylene dichloride (70ml) then, stirred themixture 5 minutes, remove below organic layer (containing solid).Add charcoal (2g, Norit SX) in organic layer, the 15 minutes after-filtration that at room temperature stir the mixture with methylene dichloride (40ml) rinsing filter cake, are used H₂The filtrate that O (100ml) washing merges.The evaporation dichloromethane layer obtains the yellow solid title compound.

δ_H(CDCl₃)：7.07(1H，dt)，7.15(1H，dt)，7.24(1H，t)，7.35(1H，dd)，7.62(1H，t)，7.92(1H，d)，8.02(1H，d)，8.11(1H，d)，8.89(1H，d)。

Mass spectrum: C₁₅H₉N₂SO₂F theoretical value: 300; Measured value: 301 (MH⁺).

Illustrate 37

8-amino-3-(3-fluorine)-thiophenyl quinoline (D37)

(1.7g, 30.4mmol) (1.2ml, 21mmol) suspension in is heated to 50 ℃ at THF (20ml), water (2ml) and acetate with iron powder.(1.8g 6mmol) adds in the mixture in batches, keeps temperature to be lower than 60 ℃ with 8-nitro-3-(3-fluorobenzene)-sulfenyl quinoline (D36) to use 15 minutes then.60 ℃ of following stirredreaction mixtures 5 hours, add toluene (5ml) afterwards.After being cooled to 60 ℃, through the silica filler filtering mixt, with toluene (2 * 20ml) washings.Vacuum is removed volatile matter, with the silica gel chromatography resistates of purifying, uses the ethyl acetate/hexane gradient elution, obtains solid title compound (1.6g, 5.7mmol, 96%).

δ_H(CDCl₃)：5.0(2H，br.s)，6.92-7.38(7H，m)，8.12(1H，d)，8.67(1H，d)；

Mass spectrum: C₁₅H₁₁N₂SF theoretical value: 270; Measured value: 271 (MH⁺).

Illustrate 38

8-iodo-3-(3-fluorine)-thiophenyl quinoline (D38)

(1.4g, trifluoroacetic acid 5.2mmol) (5ml) solution for vacuum concentration is dissolved in the oily matter that obtains in the acetonitrile (10ml) with 8-amino-3-(3-fluorine)-thiophenyl quinoline (D37).(0.91ml is in acetonitrile 7.78mmol) (10ml) solution then it to be added drop-wise to ice-cold nitrous acid straight butyl.This temperature stirredreaction mixture 10 minutes, add then in batches iodate tetra-n-butyl ammonium (3.8g, 10.4mmol).After the stirring atroom 1 hour, vacuum concentrated mixture, resistates is purified with silica gel chromatography, uses the ethyl acetate/hexane gradient elution, obtains solid title compound (D38) (1.13g, 3.0mmol, 57%);

Mass spectrum: C₁₅H₉NSFI theoretical value: 281; Measured value: 282 (MH⁺).

Illustrate 39

8-iodo-3-(3-fluorine)-benzenesulfonyl quinoline (D39)

Methylene dichloride (10ml) solution with methyl alcohol (3ml) solution-treated 8-iodo-3-(3-the fluorine)-thiophenyl quinoline (D38) (754mg 2.0mmol) of peroxide phthalic acid one magnesium hexahydrate (2g, technical grade).40 ℃ ofheated mixt 12 hours, use 10% sodium sulfite aqueous solution (20ml) and methylene dichloride (20ml) to handle then.Isolate organic phase, use the washing of saturated sodium bicarbonate aqueous solution (20ml) and salt solution (5ml) successively, concentrate then, resistates is purified with the flash chromatography on silica gel method, with hexane-methylene dichloride wash-out, obtains light yellow solid title compound (D39) with 50% yield;

δ_H(CDCl₃)：7.30(1H，dt)，7.41(1H，t)，7.5(1H，dt)，7.73(1H，dt)，7.83(1H，d)，7.97(1H，d)，8.52(1H，d)，8.78，(1H，d)，9.32(1H，d)；

Mass spectrum: C₁₅H₉NO₂SFI theoretical value: 313; Measured value: 314 (MH⁺).

Embodiment 1

8-(4-methyl-piperazine-1-yl)-3-benzenesulfonyl quinoline (E1)

Under argon gas atmosphere, in 120 ℃ of oil baths, with 3-iodo-8-(4-methyl-piperazine-1-yl)-quinoline (D2) and 3-bromo-8-(4-methyl-piperazine-1-yl)-quinoline (D1) 4: 1 mixtures, Sodium phenylsulfinate dihydrate (2.52g (1.5g), 12.6mmol) and cupric iodide (I) (2.4g, 12.6mmol) at N, stirred 40 hours in the dinethylformamide (25ml).In the reaction mixture that is cooled to room temperature, add 5% sodium bicarbonate aqueous solution (100ml) and methylene dichloride (100ml), simultaneously vigorous stirring.Leach insolubles, (3 * 20ml) wash and discard with methylene dichloride.Be transferred in the separating funnel filtrate and washings and layering.Water layer extracts with methylene dichloride (100ml), organic extract liquid water (100ml) washing of merging, dry (MgSO₄) and vacuum concentration, obtain oily matter (0.9g).Oily matter is purified with silica gel chromatography, use the ethanol/methylene gradient elution, obtain orange (0.28g, Rf0.11, ethanol/methylene 1: 19).Make this material by strong cation exchange (SCX) post, further purify, at first use methanol-eluted fractions (cut discards), use methyl alcohol/ammoniacal liquor-880 (10: 1) wash-out then, obtain orange oily title compound (E1) (0.152g, 0.41mmol, 7% (through two steps));

δ_H(CDCl₃)2.40(3H，s)，2.72-2.76(4H，m)，3.44(4H，br，s)，7.25-7.27(1H，m)，7.48-7.61(5H，m)，7.99-8.02(2H，m)，8.75(1H，d，J＝2.4Hz)，9.21(1H，d，J＝2.4Hz)；

Mass spectrum: C₂₀H₂₁N₃O₂S theoretical value: 367; Measured value: 368 (MH⁺).

Embodiment 1 (another kind of preparation method 1)

8-(4-methyl-piperazine-1-yl)-3-benzenesulfonyl quinoline (E1)

With 8-amino-3-benzenesulfonyl quinoline (D5) (38.8g, trimethyl carbinol 137mmol) (360ml) solution with two-(2-chloroethyl) amine hydrochlorate (40g, 138mmol) and yellow soda ash (72g, 0.68mol) processing.Heating vigorous reflux (about 100 ℃)mixture 16 hours, add then another part two-(25g 86mmol), and continuesheating 4 hours to (2-chloroethyl) amine hydrochlorate again.Cooling solution, 1: 1 mixture of adding saturated sodium bicarbonate aqueous solution and 10% sodium thiosulfate solution (2L).At room temperature continue to stir 16 hours, then, (3 * 500ml) extract water with methylene dichloride, the organic phase dried over mgso that merges, vacuum-evaporation is also purified on quick 75 chromatographic instruments of Biotage (1kg silica gel), obtain free alkali form title compound (E1) (11.6g), its spectrum is consistent with the spectrum of this compound for preparing with first method.

The part of this product is handled with 1M HCl diethyl ether solution, and evaporation obtains its yellow solid hydrochloride then;

δ_H(CDCl₃)2.95(3H，d)，2.38-3.52(4H，m)，4.01-4.06(2H，m)，4.19-4.26(2H，m)，7.60(2H，t)，7.70(1H，t)，7.96(1H，t)，8.07(2H，s)，8.09(2H，s)，9.34(1H，d)，9.63(1H，d)，12.9(1H，br s)。

Embodiment 1 (another kind of preparation method 2)

8-(4-methyl-piperazine-1-yl)-3-benzenesulfonyl quinoline (E1)

With 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (E16) (200mg0.55mmol) suspension in ethanol (4ml) use acetate (100 μ l), 37% formaldehyde successively methanol solution (formalin) (0.1ml) and the Amberlyst cyano group borohydride of resin-bonded (about 3mmol/g, 0.5g) processing.Stirring atroom mixture 1 hour also filters, and filtrate is absorbed on the SCX post.Use washing with alcohol, use the eluant solution of 3% ammonia in 7% methanol aqueous solution then.Evaporating solns, resistates is purified (with methylene chloride-methanol-NH with the flash chromatography on silica gel method₃Aqueous solution wash-out), obtain title compound (E1), its spectrum is consistent with the spectrum of this compound of using method for preparing.

Embodiment 1 (another kind of preparation method 3)

8-(4-methyl-piperazine-1-yl)-3-benzenesulfonyl quinoline (E1)

With 8-iodo-3-benzene sulfonyl yl-quinoline (D6) (190mg, 0.48mmol), N-methyl-piperazine (48mg, 0.48mmol), sodium tert-butoxide (65mg, 0.68mmol), four-(dibenzalacetone) two palladium [Pd₂(dba)₃] (88mg, 0.1mmol) and 1,1 '-(161mg 0.3mmol) is suspended in the anhydrous dioxane of the degassing (2ml) the diphenylphosphino ferrocene.Under argon gas atmosphere, stirred themixture 16 hours at 40 ℃.Remove and desolvate, resistates is purified (with methylene chloride-methanol ammonia soln wash-out) with the flash chromatography on silica gel method, obtains title compound (E1), and its spectrum is consistent with the spectrum of this compound of using method for preparing.

Embodiment 2

3-benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E2)

Under argon gas atmosphere; with 8-(4-methyl-piperazine-1-yl)-3-benzenesulfonyl quinoline (the E1) (0.148g that stirs; 0.4mmol), chloroformic acid 1-chloroethene ester (0.093ml; 0.85mmol) and N; N-diisopropylethylamine (0.148ml; 0.85mmol) 1, the vlil in the 2-ethylene dichloride (9ml) 1.25 hours.Reaction mixture is cooled to room temperature and vacuum concentration obtains oily matter.This oily matter is purified (using the ethanol/methylene gradient elution) with silica gel chromatography, merges the cut (Rf0.9, ethanol/methylene 1: 19) that contains main ingredient.The purification thing is dissolved in the methyl alcohol (15ml) again, and this solution of backflow is 1 hour under argon gas atmosphere.Reaction mixture to room temperature and vacuum concentration obtains solid, it is stirred with ether (5ml), and filtration obtains title compound (E2) (0.08g, 0.21mmol, 51%);

δ_H(d₆-DMSO)3.32(4H，br s)，3.55(4H，br s)，7.35(1H，d，J＝6.5Hz)，7.63-7.77(4H，m)，7.86(1H，d，J＝7.4Hz)，8.10(2H，m)，9.10(1H，d，J＝2.4Hz)，9.21(2H，s)，9.24(1H，d，J＝2.4Hz)；

Mass spectrum: C₁₉H₁₉N₃O₂S theoretical value: 353; Measured value: 354 (MH⁺).

Embodiment 2 (another kind of preparation method)

3-benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E2)

(35.7g, 78.8mmol), 1, the mixture of the 4-dioxane (200ml) and the 4M HCl aqueous solution (200ml) at room temperature stirred 2 hours, then evaporating solvent with 8-(tert-butoxycarbonyl) piperazine-1-base-3-benzenesulfonyl quinoline (D7).With resistates coevaporation several from toluene, crystallization goes out resistates from hot ethanol, obtains yellow crystalline solid title compound (E2) (18.9g, 68%);

δ_H(d_b-DMSO)3.32(4H，br s)3.55(4H，br s)，7.35(1H，d，J＝6.5Hz)，7.63-7.77(4H，m)，7.86(1H，d，J＝7.4Hz)，8.10(2H，m)，9.10(1H，d，J＝2.4Hz)，9.21(2H，s)，9.24(1H，d，J＝2.4Hz)；

Mass spectrum: C₁₉H₁₉N₃O₂S theoretical value: 353; Measured value: 354 (MH⁺);

Fusing point: 200 ℃ (phase transformation), 270-274 ℃ (decomposition).

Embodiment 3

3-(2-chlorine) benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E3)

Will two-(2-chloro-ethyl)-amine hydrochlorate (0.36g, 1.89mmol) and yellow soda ash (0.50g, (0.30g is in propyl carbinol 0.94mmol) (10ml) suspension 4.72mmol) to join 8-amino-3-(2-chlorine) benzenesulfonyl quinoline (D10).With the suspension reflux that stirs 48 hours.Reaction mixture is to room temperature, with methylene dichloride (50ml) dilution, water (50ml) washing soln, dry (MgSO₄) and vacuum concentration obtain oily matter.Oily matter is purified (using the ethanol/methylene gradient elution) with silica gel chromatography, obtain 3-(2-chlorobenzene alkylsulfonyl)-8-(4-methylpiperazine-1-yl) quinoline (0.17g, 44%) oily matter.Under argon gas atmosphere; with 3-(2-chlorobenzene alkylsulfonyl)-8-(4-methylpiperazine-1-yl) quinoline (0.17g that stirs; 0.42mmol), chloroformic acid 1-chloroethene ester (0.14ml; 1.27mmol) and N; N-diisopropylethylamine (0.22ml; 1.27mmol) 1, the vlil in the 2-ethylene dichloride (8ml) 1 hour.Reaction mixture is to room temperature, and vacuum concentration obtains oily matter.Oily matter is dissolved in the methyl alcohol (10ml) again, and reflux solution is 1 hour under argon gas atmosphere.Reaction mixture to room temperature and vacuum concentration obtains solid, and this solid is purified with preparation HPLC.Pure products is stirred with 1M HCl/ ether (5ml) and methyl alcohol (5ml), and the resulting mixture of vacuum-evaporation obtains title compound (E3) then;

δ_H(CD₃OD)3.31(4H，br s)，3.53(4H，br s)，7.57(1H，d)，7.61(1H，d)，7.69(2H，t)，7.75(1H，t)，7.89(1H，d)，8.48(1H，d)，9.10(1H，s)，9.25(1H，s)；

Mass spectrum: C₁₉H₁₈ClN₃O₂S theoretical value: 387; Measured value: 388 (MH⁺).

Embodiment 4

3-(3-chlorine) benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E4)

With the method that is similar to embodiment 3 (E3), make this compound by 8-amino-3-(3-chlorine) benzenesulfonyl quinoline (D11);

δ_H(CD₃OD)3.31(4H，br s)，3.53(4H，br s)，7.56-7.64(2H，m)，7.69-7.76(2H，m)，7.87(1H，d)，8.01(1H，d)，8.13(1H，s)，9.12(1H，s)，9.29(1H，s)；

Mass spectrum: C₁₉H₁₈ClN₃O₂S theoretical value: 387,389; Measured value: 388,390 (MH⁺).

Embodiment 5

3-(2-fluorine) benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E5)

With the method that is similar to embodiment 3 (E3), make this compound by 8-amino-3-(2-fluorine) benzenesulfonyl quinoline (D12);

δ_H(CD₃OD)3.51(4H，br s)，3.59(4H，br s)，7.30(1H，t)，7.49(1H，t)，7.54(1H，d)，7.72(2H，t)，7.86(1H，d)，8.23(1H，t)，9.05(1H，s)，9.27(1H，br s)；

Mass spectrum: C₁₉H₁₈FN₃O₂S theoretical value: 371; Definite value then: 372 (MH⁺).

Embodiment 6

3-(4-chlorine) benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E6)

With the method that is similar to embodiment 3 (E3), make this compound by 8-amino-3-(4-chlorine) benzenesulfonyl quinoline (D13);

δ_H(CD₃OD)3.54-3.57(8H，br s)，7.63(2H，d)，7.84(2H，br s)，8.03-8.06(1H，m)，8.12(2H，d)，9.39(2H，br s)；

Mass spectrum: C₁₉H₁₈ClN₃O₂S theoretical value: 387; Measured value: 388 (MH⁺).

Embodiment 7

3-(3-fluorine) benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E7)

With the method that is similar to embodiment 3 (E3), make this compound by 8-amino-3-(3-fluorine) benzenesulfonyl quinoline (D14);

δ_H(D₃OD)3.53-3.68(8H，m)，7.41-7.56(2H，m)，7.62-7.75(2H，m)，7.85-7.95(3H，m)，9.09(1H，d)，9.27(1H，d)；

Mass spectrum: C₁₉H₁₈FN₃O₂S theoretical value: 371; Measured value: 372 (MH⁺).

Embodiment 8

3-(4-bromo-2-trifluoromethoxy) benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E8)

With the method that is similar to embodiment 3 (E3), make this compound by 8-amino-3-(4-bromo-2-trifluoromethoxy) benzenesulfonyl quinoline (D15);

δ_H(CD₃OD)3.54(4H，m)，3.60(4H，m)，7.58(1H，dd)，7.66(1H，t)，7.74(1H，t)，7.86(2H，dd)，8.30(1H，d)，9.03(1H，d)，9.2 3(1H，d)；

Mass spectrum: C₂₀H₁₇BrF₃N₃O₃S theoretical value: 515,517; Measured value: 516,518 (MH⁺).

Embodiment 9

8-piperazine-1-base-3-(3-trifluoromethyl) benzenesulfonyl quinoline hydrochloride (E9)

(0.33g adds 4M HCl (10ml) in dioxane 0.63mmol) (10ml) solution to 8-(4-tert-butoxycarbonyl) piperazine-1-base-3-(3-trifluoromethyl) the benzenesulfonyl quinoline (D8) that stirs.Stir after 4 hours, vacuum evaporating solvent obtains colorless solid title compound (E9) (0.30g, 97%);

δ_H(CD₃OD)3.54-3.63(8H，m)，7.88-8.00(3H，m)，8.03-15(2H，m)，8.44(2H，d)，9.48(1H，d)，9.56(1H，d)；

Mass spectrum: C₂₀H₁₈F₃N₃O₂S theoretical value: 421; Definite value then: 422 (MH⁺).

Embodiment 10

7-chloro-3-benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E10)

At room temperature, (19mg, (54mg is in Glacial acetic acid 0.14mmol) (0.5ml) solution 0.14mmol) to join the 3-benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E2) of stirring with N-neoprene imide.After 16 hours, remove and desolvate, separate monochlor(in)ate product (10-90% acetonitrile solution) by preparation reverse phase gradient chromatography.Except that after desolvating, resistates is dissolved in the methyl alcohol, and handles with the diethyl ether solution (1M) of hydrogenchloride.Remove molten punishment, obtain title compound (E10) (9mg, 17%);

δ_H(CDCl₃)3.4(4H，br.m)，3.6(4H，v.br m)，7.61(3H，m)，7.68(2H，t)，8.05(2H，d)，8.77(1H，d)，9.22(1H，d)，9.74(2H，br NH₂)；

Mass spectrum: C₁₉H₁₈ClN₃O₂S theoretical value: 387,389; Measured value: 388,390 (ES⁺) (MH⁺).

Embodiment 11

6-methyl-3-benzenesulfonyl-8-piperazine-1-yl-quinoline hydrochloride (E11)

With the method that is similar to embodiment 3 (E3), make this compound by 8-amino-6-methyl-3-benzenesulfonyl quinoline (D16);

δ_H(CD₃OD)2.51(3H，s)，3.30(4H，brs)，3.55(4H，brs)，7.32(1H，s)，7.26-7.67(4H，m)，8.07(2H，d)，8.88(1H，d)，9.14(1H，d)；

Mass spectrum: C₂₀H₂₁N₃O₂S theoretical value: 367; Measured value: 368 (MH⁺).

Embodiment 12

(R)-8-(3-methyl) piperazine-1-base-3-benzenesulfonyl quinoline hydrochloride (E12)

Under argon gas atmosphere, (200mg 0.51mmol) is dissolved in the no water degasification dioxane (4ml) with 8-iodo-3-benzenesulfonyl quinoline (D6).In this solution, add sodium tert-butoxide (68mg, 0.71mmol) and (R)-(-)-(61mg 0.61mmol), adds catalysis punishment suspension to the 2-methylpiperazine then under argon gas atmosphere.The catalysis punishment is by with three-(dibenzalacetone) two palladiums (0) (14mg, 0.015mmol) and 2-dicyclohexyl phosphino--2 '-(N, the N-dimethylamino) (18mg, 0.015mmol) the mixture sonication in no water degasification dioxane (10ml) made biphenyl in 2 minutes.This mixture stirred 5 hours at 40 ℃, and then added another part catalyzer (make as stated above, its amount reduces by half), and continued to stir 16 hours at 40 ℃.

Filtering mixt also removes and desolvates.Resistates is dissolved in the methyl alcohol, and, removes impurity with methanol-eluted fractions downwards by the SCX ion exchange column.Reclaim product with 15%0.880 ammoniacal liquor methanol solution wash-outs.Remove and desolvate, resistates is dissolved in the methyl alcohol, and handle with the diethyl ether solution (1M) of hydrogenchloride.Remove and desolvate,, obtain title compound (E12) (40mg16%) resistates recrystallization from ethanol;

δ_H(CD₃OD)：1.40(3H，d)，2.96(1H，t)，3.19(1H，m)，3.51(2H，m)，3.69(1H，m)，3.95(2H，d)，7.46(1H，d)，7.62-7.70(4H，m)，7.81(1H，d)，8.09(2H，d)，8.99(1H，d)，9.22(1H，d)；

Mass spectrum: C₂₀H₂₁N₃O₂S theoretical value: 367; Measured value: 368 (MH⁺).

Embodiment 13

(S)-8-(3-methyl) piperazine-1-base-3-benzenesulfonyl quinoline hydrochloride (E13)

With the method that is similar to embodiment 12 (E12), replace (R)-(-)-2-methylpiperazine with (S)-(+)-2-methylpiperazine, make yellow solid title compound (E13) (77mg, 37%);

δ_H(CD₃OD)：1.40(3H，d)，2.96(1H，t)，3.19(1H，m)，3.51(2H，m)，3.69(1H，m)，3.95(2H，d)，7.46(1H，d)，7.62-7.70(4H，m)，7.81(1H，d)，8.09(2H，d)，8.99(1H，d)，9.22(1H，d)；

d(62.9MHz，CD₃OD)C16.7(CH₃)，45.1(CH₂)，48.4(CH₂)，53.3(CH)，56.8(CH₂)，122.5(CH)，125.8(CH)，129.4(2×HC)，130.0(C)，130.6(CH)，131.3(2×CH)，135.6(CH)，137.0(C)，140(CH)，142.7(C)，144.5(C)，146.4(CH)，149.0(C)。

Mass spectrum: C₂₀H₂₁N₃O₂S theoretical value: 367; Measured value: 368 (MH⁺).

Fusing point: 266-269 ℃ (decomposition) (crystallization from IPA).

Embodiment 14

The high piperazine of 8--1-base-3-benzenesulfonyl quinoline hydrochloride (E14)

The high piperazine of 8-(tert-butoxycarbonyl)-1-base-3-benzenesulfonyl quinoline (D9) crude product is suspended in the mixture of dioxane (2ml) and 4M hydrochloric acid (2ml) and stirs and formed homogeneous solution in 1 hour at 80 ℃.Remove and desolvate, resistates is dissolved in the methyl alcohol, and, use methanol-eluted fractions downwards by the SCX ion exchange column.Reclaim product with the further wash-out of 15%0.880 ammoniacal liquor methanol solutions.Remove and desolvate, handle resistates with the diethyl ether solution (1M) of hydrogenchloride.Remove and desolvate,, obtain title compound (E14) (20mg, 10%) resistates recrystallization from ethanol;

δ_H(CD₃OD)：2.31(2H，m)，3.45(2H，m)，3.55(2H，m)，3.74(4H，m)，7.40(1H，d)，7.60-7.70(5H，m)，8.08(2H，m)，8.94(1H，d)，9.18(1H，d)；

Mass spectrum: C₂₀H₂₁N₃O₂S theoretical value: 367; Measured value: 368 (MH⁺).

Embodiment 15

8-((S)-2-methyl-piperazine-1-yl)-3-benzenesulfonyl-quinoline hydrochloride (E15)

According to the method for explanation 7 (D7), replace piperazine-1-t-butyl formate with (S)-3-methyl-piperazine-1-t-butyl formate, make (S)-3-methyl-4-(3-benzene sulfonyl yl-quinoline-8-yl)-piperazine-1-t-butyl formate.Under the described condition of embodiment 2 (another kind of preparation method), handle this product then, obtain title compound (E15);

δ_H(CD₃OD)：0.92(3H，d)，3.25(1H，m)，3.43(3H，m)，3.57(2H，m)，4.09(1H，brs)，7.64(2H，t)，7.71(1H，t)，7.90(1H，t)，7.98(1H，d)，8.14(3H，m)，9.38(1H，s)，9.39(1H，s)；

Mass spectrum: C₂₀H₂₁N₃O₂S theoretical value: 367; Measured value: 368 (MH⁺).

Embodiment 16

3-benzenesulfonyl-8-piperazine-1-yl-quinoline (E16), (free alkali of E2)

In the 100ml three-necked flask, add Pd₂(dba) 2 (174mg; 0.19mmol; 0.03 8-allusion quotation-3-benzenesulfonyl quinoline (D6) (2.5g equivalent); 6.33mmol), 1,1 '-two-diphenylphosphino ferrocene (316mg, 0.57mmol), sodium tert-butoxide (851mg; 8.86mmol; 1.4 equivalent) and piperazine (2.72g, 31.6mmol, 5 equivalents).With the flask emptying, and fillnitrogen 4 times, add then anhydrous 1,4-dioxane (17.5ml, 7 volumes).Stir the mixture and 40 ℃ the heating 16.5 hours.

The cooling dark solution adds methylene dichloride (12.5ml) and uses H to room temperature₂O (12.5ml) washing soln.Contain water lotion with dichloromethane extraction, (2 * 12.5ml) extract the organic layer of merging with 5M HCl.The water layer that merges washs with methylene dichloride (2.5ml), and is transferred in the Erlenmeyer flask, adds methylene dichloride (12.5ml), and cool off flask in ice/water-bath.Stir adding 10M aqueous sodium hydroxide solution (13ml) down, all dissolve until solid at the stirring at room mixture then.Remove the below organic layer, water layer extracts with methylene dichloride (7.5ml), and the organic layer of merging is evaporated to about 5ml.Add octane-iso (2.5ml) in deep brown solution, form crystallization, stirring atroom mixture 5 minutes is then with 5 minutes adding octane-iso (22.5ml).Mixture was at room temperature worn out 1.5 hours, cooled off 30 minutes in ice/water-bath then, mixture is filtered, filter cake washs with octane-iso (5ml).The drying under reduced pressure filter cake obtains title compound E16, yield: 1.67g, 75%.

δ_H(CDCl₃)：1.6(1H，bs)，3.18(4H，m)，3.34(4H，m)，7.27(1H，m)，7.49-7.60(5H，m)，8.01(2H，dd)，8.75，(1H，d)，9.21(1H，d)。

Embodiment 17

8-(4-ethyl-piperazine-1-yl)-3-benzenesulfonyl quinoline hydrochloride (E17)

With 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (E16) (200mg; 0.55mmol) ethanol (4ml) suspension use acetate (100 μ l), acetaldehyde (100mg successively; 2.3mmol) and the Amberlyst cyano group borohydride of resin-bonded (about 3mmol/g 0.5g) handles.Stirring atroom mixture 18 hours filters then, and filtrate is absorbed on the SCX post.Use washing with alcohol, and wash with the solution of 3% ammonia in 7% methanol aqueous solution.Evaporating solns, resistates is purified (with methylene chloride-methanol-NH with the flash chromatography on silica gel method₃Aqueous solution wash-out), obtain the solution of the free alkali of title compound.Handle with this solution evaporation and with the HCl diethyl ether solution of 1M, crystallization from Virahol then obtains yellow solid title compound (E17).

δ_H(CDCl₃)：1.54(3H，t)，3.22(2H，q)，3.27-3.91(8H，m)，7.23-7.70(m，6H)，8.03(2H，d)，8.80(1H，s)，9.22(1H，s)，12.5(1H，br.s)；

Mass spectrum: C₁₇H₂₃N₃O₂S theoretical value: 381; Measured value: 382 (MH⁺).

Embodiment 18-22 (E18-22)

3-aryl sulfonyl-8-iodine quinoline (be derived from suitable mercaptan, be listed as follows, adoptgeneral preparation method 1 or 2) with suitable replacement replaces 3-benzenesulfonyl-8-iodine quinoline (D6), prepares the compound of embodiment 18-22 according to the method forembodiment 16.

Embodiment	Q1	General preparation method	Raw material mercaptan	M+H+
					18	2-Me	1	2-methyl-benzenethiol	368
19	2-OMe	1	2-methoxyl group-benzenethiol	384
					20	4-Me	1	4-methyl-benzenethiol	368
21	4-F	2	4-fluoro-benzenethiol	372
					22	2-CF3	2	2-trifluoromethyl-benzenethiol	422

Embodiment 23-31 (E23-31)

3-aryl sulfonyl-8-iodine quinoline with suitable replacement (is derived from suitable mercaptan; be listed as follows; adoptgeneral preparation method 1 or 2) replace 3-benzenesulfonyl-8-iodine quinoline (D6), prepare the compound of embodiment 23-31 according to the described method of embodiment 1 (another kind of preparation method 3).

Embodiment	Q1	General preparation method	Raw material mercaptan	M+H+
					23	2-Me	1	2-methyl-benzenethiol	382
24	2-OMe	1	2-methoxyl group-benzenethiol	398
					25	4-Me	1	4-methyl-benzenethiol	382
26	4-F	2	4-fluoro-benzenethiol	386

27	3-F	2	3-fluoro-benzenethiol	386
					28	2-F	2	2-fluoro-benzenethiol	386
29	4-Cl	2	4-chloro-benzenethiol	402，404
					30	3-Cl	1	3-chloro-benzenethiol	402，404
31	2-CF3	2	2-trifluoromethyl-benzenethiol	436

Embodiment 32-40 (E32-40)

3-aryl sulfonyl-8-iodine quinoline with suitable replacement (is derived from suitable mercaptan; be listed as follows; adoptgeneral preparation method 1 or 2) replace 3-benzenesulfonyl-8-iodine quinoline (D6), prepare the compound of EXAMPLE Example 32-40 according toembodiment 13 described methods.

Embodiment	Q1	General preparation method	Raw material mercaptan	M+H+
					32	2-Me	1	2-methyl-benzenethiol	382
33	2-OMe	1	2-methoxyl group-benzenethiol	398
					34	4-Me	1	4-methyl-benzenethiol	382
35	4-F	2	4-fluoro-benzenethiol	386
					36	3-F	2	3-fluoro-benzenethiol	386
37	2-F	2	2-fluoro-benzenethiol	386
					38	4-Cl	2	4-chloro-benzenethiol	402，404
39	3-Cl	1	3-chloro-benzenethiol	402，404
					40	2-CF3	2	2-trifluoromethyl-benzenethiol	436

Embodiment 41-44 (E41-44)

Adopt the method forembodiment 16 or 15, replace piperazine or 2-(S)-methylpiperazine respectively, the compound of preparation embodiment 41-44 with the amine of listing in the table.

Embodiment 45-49 (E45-49)

Adopt the method forembodiment 17, replace acetaldehyde, preparation embodiment 45-49 compound with listed amine of following table and the listed carbonyl compound of following table.

Embodiment	R1	R2	Amine	Aldehyde/ketone	M+H+
						45	iPr	H	E2	Acetone	396
46	iBu	H	E2	Isobutyric aldehyde	410
						47	2, the 2-dimethylpropyl	H	E2		2,2-dimethyl propionic aldehyde	424
48	Me	(R)-Me	E12	The methanol aqueous solution of 37% formaldehyde	382
						49	Me	(S)-Me	E13	The methanol aqueous solution of 37% formaldehyde	382

Embodiment 50

3-benzenesulfonyl 8-(1S, 4S) 2,5-diazabicyclo heptan-2-yl) quinoline hydrochloride (E50)

With 3-alkylsulfonyl-8-iodine quinoline (D6) (200mg; 0.48mMol), (1S; 4S)-2; 5-diaza-dicyclo [2.2.1] heptane-2-t-butyl formate (95mg; 0.48mmol), sodium tert-butoxide (65mg, 0.68mmol), four-(dibenzalacetone) two palladiums (0) (88mg, 0.1mmol) and 1; 1 '-(161mg 0.3mMol) is suspended in the anhydrous dioxane of the degassing (2ml) the diphenylphosphino ferrocene.Under argon gas atmosphere, stirred themixture 16 hours at 40 ℃.Remove and to desolvate, resistates is purified with silica gel chromatography, with the hexane solution wash-out of 30% ethyl acetate, with 70% yield obtain (1S, 4S)-5-(3-benzene sulfonyl yl-quinoline-8-yl)-2,5-diaza-dicyclo [2.2.1] heptane-2-t-butyl formate.With this product (160mg) with 4M hydrochloric acid (1ml) and dioxane (1ml) 80 ℃ ofstir process 30 minutes.Remove and desolvate, obtain yellow solid title compound (E50);

δ_H(MeOD-d₄)1.96(1H，d)，2.16(1H，d)，3.37(2H，m)，3.69(1H，m)，4.17(1H，m)，4.41(1H，s)，5.17(1H，s)，7.06(1H，dd)7.53-7.98(4H，m)，8.08(1H，m)，8.88(1H，d)，9.08(1H，d)， 9.00(1H，d)，9.55(1H，br，s)；

[M+1]⁺Measured value: 366 (C₂₀H₁₉N₃O₂S).

Embodiment 51

The crystallization of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (I type)

With 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (E16) (0.1g) heating for dissolving in ethyl acetate (1.7ml).Crystallisation by cooling goes out the needle-like product.Evaporating solvent obtains title compound with the quantitative recovery rate.158 ℃ of fusing points.

The characteristic of embodiment 51 compounds that write down:

Use has the infrared spectra of the Nicolet Avatar 360FT-IR spectrograph record solid product of general ATR annex.The band position that FT-IR spectrum (Fig. 1) shows is as follows: 2945,2819,1606,1590,1566,1487,1469,1447,1380,1323,1283,1247,1164,1138,1126,1107,1095,1083,1056,1026,997,964,949,919,906,879,859,824,785,761,723,705cm^-1

Use ThermNicolet 960 E.S.P. spectrographs to obtain the FT-Raman spectrum.Use the 400mW powder at sample position, by Nd:YVO₄Laser apparatus provides 1064nm to excite.With 4cm^-11200 scannings of resolving power record.The band position that FT-Raman spectrum (Fig. 2) shows is as follows: 215,252,293,304,315,338,556,705,858,997,1025,1098,1154,1363,1382,1397,1566,1584,1606 and 3059cm^-1

Adopt the X-ray powder diffraction pattern (Fig. 3) of following peek condition record product: the material that will not grind is loaded in the Si cup of top feeding.Use by the Cu anode (40kV, 40mA), variable transmission slit, the elementary and secondary shuttle Bruker D8 Advance X-ray powder diffraction instrument that draws slit and position responsive detectors to constitute obtains the powder collection of illustrative plates.In 2 θ=2-40 ° scope, use 0.0145 ° of 2 θ step (every rank 1s) to fetch data.Rotary sample in data-gathering process.Feature 2 θ XRPD angles are 6.84,8.61,10.47,13.01,15.11,15.50,16.24,16.63,17.20,18.00,19.65,21.07,21.66,22.20,22.62,23.99,25.61,26.12,26.76,27.96,28.86,29.64,30.26,30.85,31.31,32.60,33.08,33.70,34.35,35.65,36.85,38.05 and38.46 °.

Embodiment 52

The crystallization of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (II type)

With 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (E16) (0.5g) heating for dissolving in Virahol (5ml).Cooling solution stirred liquid to room temperature, cooled off 15 minutes in ice-water-bath then.Filter and collect product, 50 ℃ of following vacuum-dryings, obtain title compound, 371mg, 74%.164 ℃ of fusing points.

The characteristic of embodiment 52 compounds that write down:

Use has the Nicolet Avatar 360 FT-IR spectrographs record infrared spectra of general ATR annex.The band position that FT-IR spectrum (Fig. 4) shows is as follows: 3335,2939,2812,1585,1564,1485,1470,1443,1382,1361,1322,1310,1250,1232,1179,1158,1129,1107,1093,1061,1022,1000,950,914,862,813,774,760,727cm^-1

Use ThermNicolet 960 E.S.P. spectrographs, obtain the FT-Raman spectrum of sample in the glass test tube.Use the 400mW powder at sample position, provide 1064nm to excite by the Nd:YVO4 laser apparatus.With 4cm^-11200 scannings of resolving power record.The band position that FT-Raman spectrum (Fig. 5) shows is as follows: 216,252,288,617,701,726,863,1000,1026,1078,1153,1197,1339,1360,1381,1396,1445,1564,1584 and 3052cm^-1

Adopt the X-ray powder diffraction pattern (Fig. 6) of following peek condition record product: the material that will not grind is loaded in the Si cup of top feeding.Use by the Cu anode (40kV, 40mA), variable transmission slit, the elementary and secondary shuttle Bruker D8 Advance X-ray powder diffraction instrument that draws slit and position responsive detectors to constitute obtains the powder collection of illustrative plates.In 2 θ=2-40 ° scope, use 0.0145 ° of 2 θ step (every rank 1s) to fetch data.Rotary sample in data-gathering process.Feature 2 θ XRPD angles are 9.30,9.95,10.99,13.40,14.63,15.03,16.04,16.47,17.93,18.19,18.73,19.17,20.69,21.49,22.12,23.55,24.59,25.27,27.03,28.22,28.61,29.48,29.81,30.70,32.05,33.32,33.95,34.39,34.90,35.77,36.25,36.80,37.60,38.19,38.70 and 39.26 °.

Pharmacology data

Can test to compound according to the method that outlines among the WO98/27081.The compound of check embodiment F 1-E14, E16-40 and E44-50, it is to 5-HT₆Acceptor demonstrates excellent affinity, and at human cloned 5-HT₆On the acceptor, pKi value＞8.0.Embodiment E 15 and E41-43 compound are also checked, equally to 5-HT₆Acceptor has shown excellent affinity, and at human cloned 5-HT₆On the acceptor, pKi value 〉=7.5.

The accompanying drawing summary

Fig. 1 shows the infrared spectra of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (I type).

Fig. 2 shows the Raman spectrum of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (I type).

Fig. 3 shows the x-ray diffraction pattern of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (I type).

Fig. 4 shows the infrared spectra of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (II type).

Fig. 5 shows the Raman spectrum of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (II type).

Fig. 6 shows the x-ray diffraction pattern of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline (II type).

Claims (27)

1. formula (I) compound or pharmaceutically acceptable salt thereof:

Wherein:

R¹And R²Represent hydrogen or C independently_1-6Alkyl or R¹Be connected to R²Last formation group (CH₂)₂, (CH₂)₃Or (CH₂)₄

R³, R⁴And R⁵Represent independently hydrogen, halogen, cyano group ,-CF₃,-CF₃O, C_1-6Alkyl, C_1-6Alkoxyl group, C_1-6Alkyloyl or group-CONR⁶R⁷

R⁶And R⁷Represent hydrogen or C independently_1-6It is optional by the 5-7 of O or S atomic separation unit's fragrance or nonaromatic heterocycles that alkyl or can condense together forms;

M represents the integer of 1-4, thus when m be during greater than 1 integer, two R²Base can be connected to form group CH₂, (CH₂)₂Or (CH₂)₃

N represents the integer of 1-3;

P represents 1 or 2;

A represents group-Ar¹Or-Ar²Ar³

Ar¹, Ar²And Ar³Represent aryl or heteroaryl independently, described aryl and heteroaryl can be chosen wantonly by one or more identical or different substituting groups and replace, and described substituting group is selected from: halogen, hydroxyl, cyano group, nitro, trifluoromethyl, trifluoromethoxy, C_1-6Alkyl, trifluoro-methanesulfonyl oxy, pentafluoroethyl group, C_1-6Alkoxyl group, aryl C_1-6Alkoxyl group, C_1-6Alkylthio, C_1-6Alkoxy C_1-6Alkyl, C_3-7Cycloalkyl C_1-6Alkoxyl group, C_1-6Alkyloyl, C_1-6Alkoxy carbonyl, C_1-6Alkyl sulphonyl, C_1-6Alkyl sulfinyl, C_1-6Alkyl sulphonyl oxygen base, C_1-6Alkyl sulphonyl C_1-6Alkyl, aryl sulfonyl, aryl sulfonyl oxygen base, aryl sulfonyl C_1-6Alkyl, C_1-6Alkyl sulfonyl amino, C_1-6Alkyl amido, C_1-6The amino C of alkyl sulfonyl_1-6Alkyl, C_1-6Alkyl amido C_1-6Alkyl, Arenesulfonyl amino, aryl amido group, Arenesulfonyl amino C_1-6Alkyl, aryl amido group C_1-6Alkyl, aroyl, aroyl C_1-6Alkyl, aryl C_1-6Alkyloyl or group CONR⁸R⁹Or SO₂NR⁸R⁹, R wherein⁸And R⁹Represent hydrogen or C independently_1-6It is optional by the 5-7 of O or S atomic separation unit's fragrance or nonaromatic heterocycles that alkyl or can condense together forms.

2. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 1, R wherein¹Expression hydrogen, methyl, ethyl, sec.-propyl, isobutyl-or 2, the 2-dimethyl propyl.

3. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 2, R wherein¹Expression hydrogen.

4. according to formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-3, R wherein²Expression hydrogen, methyl or and R¹Link to each other and form (CH₂)₃Group.

5. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 4, R wherein²Expression hydrogen.

6. according to formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-3, R wherein³Expression hydrogen, methyl or halogen.

7. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 6, R wherein³Expression hydrogen.

8. according to formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-3, R wherein⁴And R⁵Represent hydrogen or methyl independently.

9. formula according to Claim 8 (I) compound or pharmaceutically acceptable salt thereof, wherein R⁴And R⁵All represent hydrogen.

10. according to formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-3, wherein n represents 1.

11. according to formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-3, wherein m and p represent 1 or 2 independently.

12. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 11, wherein m and p are 1.

13. according to formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-12, wherein A represents group-Ar¹, Ar wherein¹As defined in claim 1.

14. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 13, wherein Ar¹Expression is optional by halogen, C_1-6Alkyl, C_1-6The phenyl that alkoxyl group, trifluoromethyl or trifluoromethoxy replace.

15. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 13 or 14, wherein Ar¹Represent unsubstituted phenyl.

16. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 1, described compound is:

8-(4-methyl-piperazine-1-yl)-3-benzenesulfonyl quinoline;

3-(2-chlorine) benzenesulfonyl-8-piperazine-1-yl-quinoline;

3-(3-chlorine) benzenesulfonyl-8-piperazine-1-yl-quinoline;

3-(2-fluorine) benzenesulfonyl-8-piperazine-1-yl-quinoline;

3-(4-chlorine) benzenesulfonyl-8-piperazine-1-yl-quinoline;

3-(3-fluorine) benzenesulfonyl-8-piperazine-1-yl-quinoline;

3-(4-bromo-2-trifluoromethoxy) benzenesulfonyl-8-piperazine-1-yl-quinoline;

8-piperazine-1-base-3-(3-trifluoromethyl) benzenesulfonyl quinoline;

7-chloro-3-benzenesulfonyl-8-piperazine-1-yl-quinoline;

6-methyl-3-benzenesulfonyl-8-piperazine-1-yl-quinoline;

(R)-8-(3-methyl) piperazine-1-base-3-benzenesulfonyl quinoline;

(S)-8-(3-methyl) piperazine-1-base-3-benzenesulfonyl quinoline;

The high piperazine of 8--1-base-3-benzenesulfonyl quinoline;

8-((S)-2-methyl-piperazine-1-yl)-3-benzene sulfonyl yl-quinoline;

8-(4-ethyl-piperazine-1-yl)-3-benzenesulfonyl quinoline;

8-piperazine-1-base-3-(Toluene-2,4-diisocyanate-alkylsulfonyl)-quinoline;

3-(2-methoxyl group-benzenesulfonyl)-8-piperazine-1-yl-quinoline;

8-piperazine-1-base-3-(toluene-4-alkylsulfonyl)-quinoline;

3-(4-fluoro-benzenesulfonyl)-8-piperazine-1-yl-quinoline;

3-(2-trifluoromethyl-benzenesulfonyl)-8-piperazine-1-yl-quinoline;

8-(4-methyl-piperazine-1-yl)-3-(Toluene-2,4-diisocyanate-alkylsulfonyl)-quinoline;

3-(2-methoxyl group-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

8-(4-methyl-piperazine-1-yl)-3-(toluene-4-alkylsulfonyl)-quinoline;

3-(4-fluoro-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

3-(3-fluoro-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

3-(2-fluoro-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

3-(4-chloro-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

3-(3-chloro-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

3-(2-trifluoromethyl-benzenesulfonyl)-8-(4-methyl-piperazine-1-yl)-quinoline;

8-((S)-3-methyl-piperazine-1-yl)-3-(Toluene-2,4-diisocyanate-alkylsulfonyl)-quinoline;

3-(2-methoxyl group-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

8-((S)-3-methyl-piperazine-1-yl)-3-(toluene-4-alkylsulfonyl)-quinoline;

3-(4-fluoro-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

3-(3-fluoro-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

3-(2-fluoro-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

3-(4-chloro-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

3-(3-chloro-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

3-(3-trifluoromethyl-benzenesulfonyl)-8-((S)-3-methyl-piperazine-1-yl)-quinoline;

3-benzenesulfonyl-8-((R)-2-methyl-piperazine-1-yl)-quinoline;

3-benzenesulfonyl-8-((2R, 5S)-2,5-dimethyl-piperazine-1-yl)-the quinoline racemoid;

3-benzenesulfonyl-8-(3,3-dimethyl-piperazine-1-yl)-quinoline;

3-benzenesulfonyl-8-(six hydrogen-pyrrolo-[1,2-a] pyrazine-2-yl)-quinoline racemoid;

3-benzenesulfonyl-8-(4-sec.-propyl-piperazine-1-yl)-quinoline;

3-benzenesulfonyl-8-(4-isobutyl--piperazine-1-yl)-quinoline;

3-benzenesulfonyl-8-[4-(2,2-dimethyl-propyl group)-piperazine-1-yl]-quinoline;

3-benzenesulfonyl-8-((R)-3,4-dimethyl-piperazine-1-yl)-quinoline;

3-benzenesulfonyl-8-((S)-3,4-dimethyl-piperazine-1-yl)-quinoline; Or

3-benzenesulfonyl 8-(1S, 4S}2,5-diazabicyclo heptane-2-yl) quinoline.

17. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 1, described formula (I) compound is 3-benzenesulfonyl-8-piperazine-1-yl-quinoline.

18. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 17, described formula (I) compound is the free alkali of 3-benzenesulfonyl-8-piperazine-1-yl-quinoline.

19. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 18, described formula (I) compound is I type 3-benzenesulfonyl-8-piperazine-1-yl-quinoline, it is characterized in that:

(i) with the infrared spectra of Fig. 1 basically identical; And/or

(ii) with the Raman spectrum of Fig. 2 basically identical; And/or

(iii) with the X-ray powder diffraction pattern of Fig. 3 basically identical.

20. according to formula (I) compound or pharmaceutically acceptable salt thereof of claim 18, described formula (I) compound is II type 3-benzenesulfonyl-8-piperazine-1-yl-quinoline, it is characterized in that:

(i) with the infrared spectra of Fig. 4 basically identical; And/or

(ii) with the Raman spectrum of Fig. 5 basically identical; And/or

(iii) with the X-ray powder diffraction pattern of Fig. 6 basically identical.

21. the method for formula (I) compound or pharmaceutically acceptable salt thereof of arbitrary claim among the preparation claim 1-20 comprises:

(a) with formula (II) compound,

Wherein, R^1aDefinition with R in the claim 1¹Definition or N-protected base, R², R³, R⁴, R⁵, m, n and p definition with claim 1 and L¹It is leavings group;

With formula A-SO₂H compound reaction, or with the A-SH reaction after then carry out oxidation step, wherein the A definition is the same, sloughs R then where necessary^1aThe N-protected base; Or

(b) with formula (IV) compound

With the reaction of formula V compound,

Wherein, R^1a, R², R³, R⁴, R⁵, A, m, n and p definition with claim 1, and L²Represent suitable leavings group, then, slough R in case of necessity^1aThe N-protected base; Or

(c) with formula (VI) compound

With the reaction of formula (VII) compound,

Wherein, R^1a, R², R³, R⁴, R⁵, A, m, n and p definition with claim 1 and L³Represent suitable leavings group, then, slough R in case of necessity^1aThe N-protected base or

(d) make protected formula (I) compound deprotection; And it is optional subsequently

(e) change is other compound of formula (I) and/or forms pharmacologically acceptable salt.

22. pharmaceutical composition contains compound or pharmaceutically acceptable salt thereof and the pharmaceutically acceptable carrier or the excipient of arbitrary claim among the claim 1-20.

23. the compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-20 that is used for the treatment of.

24. be used for the treatment of the compound or pharmaceutically acceptable salt thereof of arbitrary claim among the claim 1-20 of cognitive impairment in dysthymia disorders, anxiety, Alzheimer's, the cognitive decline relevant, ADHD, obesity, slight cognitive impairment, schizophrenia, the schizophrenia and apoplexy with the age.

25. the formula of arbitrary claim (I) compound or pharmaceutically acceptable salt thereof is used for the treatment of or prevents purposes in the medicine of cognitive impairment in dysthymia disorders, anxiety, Alzheimer's, the cognitive decline relevant with the age, ADHD, obesity, slight cognitive impairment, schizophrenia, the schizophrenia and apoplexy in preparation among the claim 1-20.

26. be used for the treatment of cognitive impairment and the apoplexy in dysthymia disorders, anxiety, Alzheimer's, the cognitive decline relevant, ADHD, obesity, slight cognitive impairment, schizophrenia, the schizophrenia or be used for promoting the pharmaceutical composition of mammalian central nervous system neure growth, contain each defined formula (I) compound or pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier or excipient among the claim 1-20 with the age.

27. the formula of arbitrary claim (I) compound or pharmaceutically acceptable salt thereof is used for promoting purposes in the medicine of mammalian central nervous system neure growth in preparation among the claim 1-20.

Images